

**2001 USPHS/IDSA Guidelines for the
Prevention of Opportunistic Infections in
Persons Infected with Human
Immunodeficiency Virus**

November 28, 2001

2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus

Introduction	6
Disease-specific Recommendations	8
Pneumocystis Pneumonia.....	8
Toxoplasmic Encephalitis	10
Cryptosporidiosis.....	12
Microsporidiosis.....	13
Tuberculosis	14
Disseminated Infection with Mycobacterium avium Complex.....	15
Bacterial Respiratory Infections.....	17
Bacterial Enteric Infections	19
Bartonellosis	20
Candidiasis	21
Cryptococcosis	22
Histoplasmosis.....	23
Coccidioidomycosis	24
Cytomegalovirus Disease	24
Herpes Simplex Virus Disease.....	26
Varicella Zoster Virus Disease.....	27
Human Herpesvirus 8 Infection (Kaposi’s Sarcoma-Associated Herpes Virus)	27
Human Papillomavirus Infection.....	28
Hepatitis C Virus Infection.....	29
References	31
Table 1. Prophylaxis to Prevent First Episode of Opportunistic Disease in Adults and Adolescents Infected with Human Immunodeficiency Virus	38

Table 2.	
Prophylaxis to Prevent Recurrence of Opportunistic Disease in Adults (after chemo-therapy for acute disease) in Adults and Adolescents Infected with Human Immunodeficiency Virus.....	42
Table 3.	
Effects of Food on Drugs Used to Prevent Opportunistic Infections.....	44
Table 4.	
Effects of Medications on Drugs used to Prevent Opportunistic Infections	45
Table 5.	
Effects of Opportunistic infection Medications on Antiinfective Drugs Commonly Administered to Persons Infected with Human Immunodeficiency Virus	47
Table 6.	
Adverse Effects of Drugs Used in the Prevention of Opportunistic Infections	48
Table 7.	
Dosing of Drugs for Primary Prevention or Maintenance Therapy for Opportunistic Infections in Renal Insufficiency	49
Table 8.	
Wholesale Acquisition Costs of Agents Recommended for the Prevention of Opportunistic Infections in Adults Infected with Human Immunodeficiency Virus.....	51
Table 9.	
Immunologic Categories for Human Immunodeficiency Virus-infected Children Based on Age-specific CD4+ T-lymphocyte Counts and Percentage of Total Lymphocytes.....	52
Table 10.	
Recommended Immunization Schedule for Human Immunodeficiency Virus-infected Children.....	53
Table 11.	
Prophylaxis to Prevent First Episode of Opportunistic Disease in Infants and Children Infected with Human Immunodeficiency Virus.....	55
Table 12.	
Prophylaxis to Prevent Recurrence of Opportunistic Disease (after chemotherapy for acute disease) in HIV-infected Infants and Children	58
Table 13.	
Criteria for Starting, Discontinuing, and Restarting Opportunistic Infection Prophylaxis for Adults with human Immunodeficiency Virus Infection.....	60
Appendix.	
Recommendations to Help Patients Avoid Exposure to or Infection with Opportunistic Pathogens.....	61

Final

2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus

U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)

USPHS/IDSA Prevention of Opportunistic Infections Working Group

CO-CHAIRS:

Henry Masur, M.D.
National Institutes of Health
Bethesda, Maryland

Jonathan E. Kaplan, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

King K. Holmes, M.D., Ph.D.
University of Washington
Seattle, Washington

MEMBERS:

Beverly Alston, M.D.
National Institutes of Health
Bethesda, Maryland

Miriam J. Alter, Ph.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

Neil Ampel, M.D.
University of Arizona
Tucson, Arizona

Jean R. Anderson, M.D.
Johns Hopkins University
Baltimore, Maryland

A. Cornelius Baker
Whitman Walker Clinic
Washington, D.C.

David Barr
Forum for Collaborative HIV Research
Washington, D.C.

John G. Bartlett, M.D.
Johns Hopkins University
Baltimore, Maryland

John E. Bennett, M.D.
National Institutes of Health
Bethesda, Maryland

Constance A. Benson, M.D.
University of Colorado
Denver, Colorado

William A. Bower, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

Samuel A. Bozzette, M.D.
University of California
San Diego, California

John T. Brooks, M.D.
Centers for Disease Control and Prevention
Atlanta, GA

Victoria A. Cargill, M.D.
National Institutes of Health
Bethesda, Maryland

Kenneth G. Castro, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

Richard E. Chaisson, M.D.
Johns Hopkins University
Baltimore, Maryland

David Cooper, M.D., DS.c.
University of New South Wales
Sydney, Australia

Clyde S. Crumpacker, M.D.
Beth Isreal - Deaconess Medical Center
Boston, Massachusetts

Judith S. Currier, M.D., M.Sc.
University of California-Los Angeles Medical
Center
Los Angeles, California

Kevin M. DeCock, M.D., DTM&H
Centers for Disease Control and Prevention
Atlanta, Georgia

Lawrence Deyton, M.D., MSPH
U.S. Department of Veterans Affairs
Washington, D.C.

Scott F. Dowell, M.D., MPH
Centers for Disease Control and Prevention
Atlanta, Georgia

W. Lawrence Drew, M.D., Ph.D.
Mt. Zion Medical Center
University of California
San Francisco, California

William R. Duncan, Ph.D.
National Institutes of Health
Bethesda, Maryland

Mark S. Dworkin, M.D., MPHTM
Centers for Disease Control and Prevention
Atlanta, Georgia

Clare Dykewicz, M.D., MPH
Centers for Disease Control and Prevention
Atlanta, Georgia

Robert W. Eisinger, Ph.D.
National Institutes of Health
Bethesda, Maryland

Tedd Ellerbrock, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

Wafaa El-Sadr, M.D., MPH, MPA.
Harlem Hospital
New York, New York

Judith Feinberg, M.D.
Holmes Hospital
Cincinnati, Ohio

Kenneth A. Freedberg, M.D., M.Sc.
Massachusetts General Hospital
Boston, Massachusetts

Keiji Fukuda, MD
Centers for Disease Control and Prevention
Atlanta, Georgia

Hansjakob Furrer, M.D.
University Hospital
Berne, Switzerland

Jose M. Gatell, M.D., Ph.D.
Hospital Clinic
Barcelona, Spain

John W. Gnann, Jr., M.D.
University of Alabama
Birmingham, Alabama

Mark J. Goldberger, M.D., MPH
U.S. Food and Drug Administration
Rockville, Maryland

Sue Goldie, M.D., MPH
Harvard School of Public Health
Boston, Massachusetts

Eric P. Goosby, M.D.
U.S. Department of Health and Human Services
Washington, D.C.

Fred Gordin, M.D.
Veterans Administration Medical Center
Washington, D.C.

Peter A. Gross, M.D.
Hackensack Medical Center
Hackensack University, New Jersey

Rana Hajjeh, MD
Centers for Disease Control and Prevention
Atlanta, Georgia

Richard Hafner, M.D.
National Institutes of Health
Bethesda, Maryland

Diane Havlir, M.D.
University of California
San Diego, California

Scott Holmberg, M.D., MPH
Centers for Disease Control and Prevention
Atlanta, Georgia

David R. Holtgrave, Ph.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

Thomas M. Hooton, M.D.
Harborview Medical Center
Seattle, Washington

Douglas A. Jabs, M.D., M.B.A.
Johns Hopkins University
Baltimore, Maryland

Mark A. Jacobson, M.D.
University of California
San Francisco, CA

Harold Jaffe, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

Edward Janoff, M.D.
Veterans Administration Medical Center
Minneapolis, Minnesota

Jeffrey Jones, MD
Centers for Disease Control and Prevention
Atlanta, Georgia

Dennis D. Juranek, D.V.M, MS.c.
Centers for Disease Control and Prevention
Atlanta, Georgia

Mari Kitahata, M.D., Ph.D.
University of Washington
Seattle, Washington

Joseph A. Kovacs, M.D.
National Institutes of Health
Bethesda, Maryland

Catherine Leport, M.D.
Hospital Bichat-Claude Bernard
Paris, France

Myron J. Levin, M.D.
University of Colorado Health Science Center
Denver, Colorado

Juan C. Lopez, M.D.
Hospital Universatario Gregorio Maranon
Madrid, Spain

Jens Lundgren, M.D.
Hvidore Hospital
Copenhagen, Denmark

Michael Marco
Treatment Action Group
New York, New York

Eric Mast, M.D., MPH
Centers for Disease Control and Prevention
Atlanta, Georgia

Douglas Mayers, M.D.
Henry Ford Hospital
Detroit, Michigan

Lynne M. Mofenson, M.D.
National Institutes of Health
Bethesda, Maryland

Julio S.G. Montaner, M.D.
St. Paul's Hospital
Vancouver, Canada

Richard Moore, M.D.
Johns Hopkins Hospital
Baltimore, Maryland

Thomas Navin, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

James Neaton, Ph.D.
University of Minnesota
Minneapolis, Minnesota

Charles Nelson
National Association of People with AIDS
Washington, D.C.

Joseph F. O'Neill, M.D., MS, MPH
Health Resources and Services
Administration
Rockville, Maryland

Joel Palefsky, M.D.
University of California
San Francisco, California

Alice Pau, Pharm.D.
National Institutes of Health
Bethesda, Maryland

Phil Pellett, Ph.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

John P. Phair, M.D.
Northwestern University
Chicago, Illinois

Steve Piscitelli, Pharm.D.
National Institutes of Health
Bethesda, Maryland

Michael A. Polis, M.D., MPH
National Institutes of Health
Bethesda, Maryland

Thomas C. Quinn, M.D.
Johns Hopkins Hospital
Baltimore, Maryland

William C. Reeves, M.D., MPH
Centers for Disease Control and Prevention
Atlanta, Georgia

Peter Reiss, M.D., Ph.D.
University of Amsterdam
The Netherlands

David Rimland, M.D.
Veterans Administration Medical Center
Atlanta, Georgia

Anne Schuchat, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

Cynthia L. Sears, M.D.
Johns Hopkins Hospital
Baltimore, Maryland

Leonard Seeff, M.D.
National Institutes of Health
Bethesda, Maryland

Kent A. Sepkowitz, M.D.
Memorial Sloan-Kettering Cancer Center
New York, New York

Kenneth E. Sherman, M.D., Ph.D.
University of Cincinnati
Cincinnati, Ohio

Thomas G. Slama, M.D.
National Foundation for Infectious Diseases
Indianapolis, Indiana

Elaine M. Sloand, M.D.
National Institutes of Health
Bethesda, Maryland

Stephen A. Spector, M.D.
University of California
La Jolla, California

John A. Stewart, M.D.
Centers for Disease Control and Prevention
Atlanta, Georgia

David L. Thomas, M.D., MPH
Johns Hopkins Hospital
Baltimore, Maryland

Timothy M. Uyeki, M.D., MPH
Centers for Disease Control and Prevention
Atlanta, GA

Russell B. Van Dyke, M.D.
Tulane School of Medicine
New Orleans, Louisiana

M. Elsa Villarino, M.D., MPH
Centers for Disease Control and Prevention
Atlanta, Georgia
Anna Wald, M.D.
University of Seattle
Seattle, Washington

D. Heather Watts, M.D.
National Institutes of Health
Bethesda, Maryland

L. Joseph Wheat, M.D.
Indiana University School of Medicine
Indianapolis, Indiana

Paige Williams, Ph.D.
Harvard School of Public Health
Boston, Massachusetts

Thomas C. Wright, Jr., M.D.
Columbia University College of
Physicians and Surgeons
New York, New York

INTRODUCTION

In 1995, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA) developed guidelines for preventing opportunistic infections (OIs) in persons infected with human immunodeficiency virus (HIV) (1-3). These guidelines, written for health-care providers and patients, were revised in 1997 (4) and again in 1999 (5), and have been published in the *MMWR* (1,4,5), *Clinical Infectious Diseases* (2,6,7), the *Annals of Internal Medicine* (3,8), the *American Family Physician* (9,10), and *Pediatrics* (11); accompanying editorials have appeared in *JAMA* (12,13). Response to these guidelines (e.g., the many requests for reprints, numerous web site contacts, and observations from health-care providers) suggests they have served as a valuable reference for HIV care providers. Because the 1995, 1997, and 1999 guidelines included ratings indicating the strength of each recommendation and the quality of supporting evidence, readers have been able to assess the relative importance of each recommendation.

Since AIDS was first recognized 20 years ago, remarkable progress has been made in improving the quality and duration of life of HIV-infected persons in the industrialized world. During the first decade of the epidemic, this improvement occurred because of better recognition of opportunistic disease processes, better therapy for acute and chronic complications, and the introduction of chemoprophylaxis against important opportunistic pathogens. The second decade of the epidemic has witnessed extraordinary progress in developing highly active antiretroviral therapies (HAART) as well as continuing progress in preventing and treating individual OIs. HAART has reduced the incidence of OIs and extended life substantially (14-16). HAART is the most effective approach to preventing OIs and should be considered for all HIV-infected persons who qualify for such therapy (14-16). However, some patients are not ready or able to take HAART, and others have tried HAART regimens, but therapy has failed. Such patients will benefit from prophylaxis against OIs (15). In addition, prophylaxis against specific OIs continues to provide survival benefits even among persons who are receiving HAART (15).

Since HAART was introduced in the United States in 1995, it has become increasingly clear that chemoprophylaxis for opportunistic infection need not necessarily be life-long. Antiretroviral therapy can restore immune function. The period of susceptibility to opportunistic processes continues to be accurately indicated by the CD4+ T-lymphocyte count for patients who are receiving HAART. Thus, a strategy of stopping primary or secondary prophylaxis for certain patients whose immunity has improved as a consequence of HAART seems logical. Stopping prophylactic regimens can simplify treatment, reduce toxicity and drug interactions, lower cost of care, and potentially facilitate adherence to antiretroviral regimens.

In 1999, the USPHS/IDSA guidelines suggested that it may be safe to stop primary or secondary prophylaxis for some (but not all) pathogens if HAART has led to an increase in CD4+ T-lymphocyte counts above specified threshold levels. Recommendations were made for only those pathogens for which adequate clinical data were available. Data generated since 1999 continue to support these recommendations and allow additional recommendations to be made concerning the safety of stopping primary or secondary prophylaxis for other pathogens.

For recommendations on discontinuation of chemoprophylaxis, readers will note that criteria vary by such factors as duration of CD4+ T lymphocyte count increase, and, in the case of secondary prophylaxis, duration of treatment of the initial episode of disease. These differences reflect the criteria used in specific studies. Therefore, some inconsistency in the format of these criteria is unavoidable.

Although considerable data are now available concerning discontinuing primary and secondary OI prophylaxis, essentially no data are available regarding restarting prophylaxis when the CD4+ lymphocyte count decreases again to levels at which the patient is likely to again be at risk for OI. For primary prophylaxis, whether to use the same threshold at which prophylaxis may be stopped (derived from data in studies addressing prophylaxis discontinuation), or to use the threshold below which initial prophylaxis is recommended, is unknown. Therefore in this revision of the guidelines, in some cases ranges are provided for restarting primary or secondary prophylaxis. For prophylaxis against *Pneumocystis carinii* pneumonia (PCP), the suggested threshold for restarting both primary and secondary prophylaxis is 200 cells/ μ L. For all these recommendations, the Roman numeral ratings reflect the lack of data available to assist in making these decisions (see description of rating system below).

During the development of these revised guidelines, working group members reviewed published manuscripts as well as abstracts and material presented at professional meetings. A series of teleconferences were held to develop the revisions. In this revision, information and recommendations which are new since the 1999 publication are indicated in bold.

Major Changes in these Recommendations

Major changes in the guidelines since 1999 include:

- Higher level ratings have been provided for discontinuing primary prophylaxis for PCP and MAC when CD4+ T lymphocytes have increased to >200 cells/ μ L and >100 cells/ μ L, respectively, for \geq 3 months in response to HAART (AI), and a new recommendation to discontinue primary toxoplasma prophylaxis has been provided when the CD4+ T lymphocyte count has increased to >200 cells/ μ L for \geq 3 months (AI).
- Secondary PCP prophylaxis should be discontinued in patients whose CD4+ counts have increased to > 200 cells/ μ L for \geq 3 months as a consequence of HAART (BII).
- Secondary prophylaxis for disseminated MAC may be discontinued in patients with a sustained (e.g., \geq 6 months) increase in CD4+ count to >100cells/ μ L in response to HAART if they have completed 12 months of MAC therapy and have no symptoms or signs attributable to MAC (CIII).
- Secondary prophylaxis for toxoplasmosis and cryptococcosis may be discontinued in patients with a sustained increase in CD4+ counts (e.g. \geq 6 months) to >200 cells/ μ L and >100-200cells/ μ L respectively, in response to HAART if they have completed their initial therapy and have no symptoms or signs attributable to these pathogens (CIII).
- The importance of screening all HIV-infected individuals for hepatitis C virus (HCV) is emphasized (BIII).
- Additional information about transmission of human herpesvirus 8 infection (HHV-8) is provided.
- New information on drug interactions is provided, especially with regard to rifamycins and antiretroviral drugs.
- Revised recommendations for immunization of HIV exposed/infected adults and children are provided.

How to Use the Information in This Report

For each of the 19 diseases covered in this report, specific recommendations are provided that address a) prevention of exposure to the opportunistic pathogen, b) prevention of the first episode of disease, and c) prevention of disease recurrence. Recommendations are rated by a revised version of the IDSA rating system (17). In this system, the letters A through E signify the strength of the recommendation for or against a preventive measure, and Roman numerals I through III indicate the quality of evidence supporting the recommendation (see Box).

System used to rate the strength of recommendations and quality of supporting evidence

Rating	Strength of the Recommendation
A	Both strong evidence for efficacy and substantial clinical benefit support recommendation for use. Should always be offered.
B	Moderate evidence for efficacy -- or strong evidence for efficacy but only limited clinical benefit -- supports recommendation for use. Should generally be offered.
C	Evidence for efficacy is insufficient to support a recommendation for or against use. Or evidence for efficacy might not outweigh adverse consequences (e.g., drug toxicity, drug interactions) or cost of the chemoprophylaxis or alternative approaches. Optional.
D	Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered.
E	Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.
	Quality of evidence supporting the recommendation
I	Evidence from at least one properly randomized, controlled trial.
II	Evidence from at least one well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than one center), or from multiple time-series studies. Or dramatic results from uncontrolled experiments.
III	Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.

Because of their length and complexity, the tables in this report are grouped together, following the references. The tables appear in the following order: dosages for prophylaxis to prevent first episode of opportunistic disease in HIV-

infected adults and adolescents (Table 1); dosages for prophylaxis to prevent recurrence of opportunistic disease in HIV-infected adults and adolescents (Table 2); effects of food on drugs used to treat OIs (Table 3); effects of medications on drugs used to treat OIs (Table 4); effects of OI medications on drugs commonly administered to HIV-infected persons (Table 5); adverse effects of drugs used to manage HIV infection (Table 6); dosages of drugs for prevention of OIs for persons with renal insufficiency (Table 7); costs of agents recommended for the prevention of OIs in adults with HIV infection (Table 8); immunologic categories for HIV-infected children (Table 9); immunization schedule for HIV-infected children (Table 10); dosages for prophylaxis to prevent first episode of opportunistic disease in HIV-infected infants and children (Table 11); dosages for prophylaxis to prevent recurrence of opportunistic disease in HIV-infected infants and children (Table 12); and criteria for discontinuing and restarting OI prophylaxis for adult patients with HIV infection (Table 13). Recommendations advising patients how to prevent exposure to opportunistic pathogens appear in the appendix at the end of this report.

This report is oriented toward the prevention of specific opportunistic infections in HIV-infected persons in the United States and other industrialized countries. Recommendations for use of HAART, which is designed to prevent immunologic deterioration, to restore immune function and delay the need for many of the chemoprophylactic strategies described in this report, were originally published elsewhere (14) and are updated regularly (www.hivatis.org) (16).

Pamphlets for patients regarding prevention of opportunistic infections can be obtained from the HIV/AIDS Treatment Information Service (ATIS) by calling (800) 448-0440, (301) 519-0459 (international), or (888) 480-3739 (TTY). They also can be accessed on both the CDC and HIVATIS websites (www.cdc.gov/hiv/pubs/brochure.htm and www.hivatis.org).

New data on prevention of OIs in HIV-infected persons are emerging, and randomized controlled trials addressing some unresolved issues in OI prophylaxis are ongoing. The OI Working Group review emerging data routinely and will update these guidelines on a regular basis.

DISEASE-SPECIFIC RECOMMENDATIONS

***Pneumocystis carinii* Pneumonia**

Prevention of Exposure

1. Although some authorities recommend that persons with human immunodeficiency virus (HIV) infection who are at risk for *P. carinii* pneumonia (PCP) not share a hospital room with a patient who has PCP, data are insufficient to support this recommendation as standard practice (CIII).

Prevention of Disease

Initiation of Primary Prophylaxis

2. Adults and adolescents who have HIV infection (including pregnant women and those on HAART) should receive chemoprophylaxis against PCP if they have a CD4+ T-lymphocyte count of less than 200/ μ L (AI) or a history of oropharyngeal candidiasis (AII) (18-20). Persons who have a CD4+ T-lymphocyte percentage of less than 14% or history of an acquired immunodeficiency syndrome (AIDS)-defining illness but do not otherwise qualify should be considered for prophylaxis (BII) (18-20). When monitoring the CD4+ T-lymphocyte count at least every 3 months is not possible, initiation of chemoprophylaxis at a CD4+ T-lymphocyte count of greater than 200 but less than 250 cells/ μ L also should be considered (BII) (19).

3. Trimethoprim-sulfamethoxazole (TMP-SMZ) is the recommended prophylactic agent (AI) (20-23). One double-strength tablet per day is the preferred regimen (AI) (23). However, one single-strength tablet per day (23) is also effective and might be better tolerated than one double strength tablet per day (AI). One double-strength tablet three times per week is also effective (BI) (24). TMP-SMZ at a dose of one double-strength tablet per day confers cross-protection against toxoplasmosis (25) and some common respiratory bacterial infections (21,26) Lower doses of TMP-SMZ also might confer such protection. For patients who have an adverse reaction that is not life-threatening, treatment with TMP-SMZ should be continued if clinically feasible; for those who have discontinued such therapy because of an adverse reaction, reinstatement of TMP-SMZ should be strongly considered after the adverse event has resolved (AII). Patients who have experienced adverse events, especially fever and rash, might better tolerate reintroduction of the drug with a gradual increase in dose (desensitization) as per published regimens (BI) (27,28) or reintroduction of TMP-SMZ at a reduced dose or frequency (CIII); up to 70% of patients can tolerate such reinstatement of therapy (26).

4. If TMP-SMZ cannot be tolerated, prophylactic regimens that can be recommended as alternatives include dapsone (BI), (21) dapsone plus pyrimethamine plus leucovorin (BI) (29,30), aerosolized pentamidine administered by the Respigard II™ nebulizer (Marquest, Englewood, Colorado) (BI), (22) and atovaquone (BI) (31,32). Atovaquone appears to be as effective as aerosolized pentamidine (31) or dapsone (BI) (32) but is substantially more expensive than the other regimens. For patients seropositive for *Toxoplasma gondii* who cannot tolerate TMP-SMZ, recommended alternatives to TMP-SMZ for prophylaxis against both PCP and toxoplasmosis include dapsone plus pyrimethamine (BI) (29,30) or atovaquone with or without pyrimethamine (CIII). The following regimens generally cannot be recommended as alternatives because data regarding their efficacy for PCP prophylaxis are insufficient for a firm recommendation: aerosolized pentamidine administered by other nebulization devices, intermittently administered parenteral pentamidine, oral pyrimethamine plus sulfadoxine, oral clindamycin plus primaquine, and intravenous trimetrexate. However, clinicians may consider using these agents in unusual situations in which the recommended agents cannot be administered (CIII).

Discontinuation of Primary Prophylaxis

5. Primary pneumocystis prophylaxis should be discontinued in adult and adolescent patients who have responded to HAART with an increase in CD4+ T lymphocyte counts to >200 cells/μL for at least 3 months (AI). In observational and randomized studies supporting this recommendation, most patients were taking antiretroviral regimens that included a protease inhibitor and most had a CD4+ T cell count greater than 200 cells/μL for at least 3 months before discontinuation of PCP prophylaxis (33-41). The median CD4+ lymphocyte count at the time prophylaxis was discontinued was >300 cells/μL, and many patients had a sustained suppression of HIV plasma RNA levels below detection limits of the assay employed. Median follow-up ranged from 6-16 months.

Discontinuation of primary prophylaxis in these patients is recommended not only because prophylaxis appears to add very little to disease prevention (for PCP, toxoplasmosis, or bacterial infections), but also because discontinuation of drug reduces pill burden, the potential for drug toxicity, drug interactions, selection of drug-resistant pathogens, and cost.

Restarting Primary Prophylaxis

6. Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to <200 cells/μL (AIII).

Prevention of Recurrence

7. Patients who have a history of PCP should be administered chemoprophylaxis (i.e., secondary prophylaxis or chronic maintenance therapy) with the regimens listed in Table 2 for life (AI) unless immune reconstitution occurs as a consequence of HAART (see Recommendation #8 below).

Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)

8. Secondary prophylaxis should be discontinued for adult and adolescent patients whose CD4+ T cell count has increased from <200 cells/μL to >200 cells/μL for at least 3 months due to HAART (BII). Reports from observational studies (37,41,42) and from a randomized trial (39), as well as a combined analysis of 8 European cohorts being followed prospectively, (43) support this recommendation. In these studies, patients had responded to HAART with an increase in CD4+ T-lymphocyte count to >200 cells/μL for at least 3 months. Most patients were taking protease inhibitor-containing regimens. The median CD4+ T-lymphocyte count at the time prophylaxis was discontinued was > 300 cells/μL. Most patients had sustained suppression of HIV plasma HIV RNA levels below the detection limits of the assay employed; the longest follow-up was 13 months. If the episode of PCP occurred at a CD4+ T lymphocyte count >200 cells/μL, it is probably prudent to continue PCP prophylaxis for life regardless of how high the CD4+ T lymphocyte count rises as a consequence of HAART (CIII).

Discontinuation of secondary prophylaxis for patients is recommended not only because prophylaxis appears to add very little to disease prevention (for PCP, toxoplasmosis, or bacterial infections), but also because discontinuation of drug reduces pill burden, the potential for drug toxicity, drug interactions, and selection of drug resistant pathogens, and cost.

Restarting Secondary Prophylaxis

Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to < 200 cells/μL (AIII), or if PCP recurred at a CD4+ T lymphocyte count >200 cells/μL (CIII).

Special Considerations

Children

10. Children born to HIV-infected mothers should be administered prophylaxis with TMP-SMZ beginning at 4-6 weeks of age (44)(AII). Prophylaxis should be discontinued for children who are subsequently found not to be infected with HIV. HIV-infected children and children whose infection status remains unknown should continue to receive prophylaxis for the first year of life. The need for subsequent prophylaxis should be determined on the basis of age-specific CD4+ T-lymphocyte count thresholds (Table 11) (AII). The safety of discontinuing prophylaxis in HIV-infected children receiving HAART has not been studied extensively.

11. Children who have a history of PCP should be administered lifelong chemoprophylaxis to prevent recurrence (44) (AI). **The safety of discontinuing secondary prophylaxis in HIV-infected children has not been studied extensively.**

Pregnant Women

12. Chemoprophylaxis for PCP should be administered to pregnant women as is done for other adults and adolescents (AIII). TMP-SMZ is the recommended prophylactic agent; dapsone is an alternative. Because of theoretical concerns regarding possible teratogenicity associated with drug exposures during the first trimester, providers may choose to withhold prophylaxis during the first trimester. In such cases, aerosolized pentamidine may be considered because of its lack of systemic absorption and the resultant lack of exposure of the developing embryo to the drug (CIII).

Toxoplasmic Encephalitis

Prevention of Exposure

1. HIV-infected persons should be tested for immunoglobulin G (IgG) antibody to *Toxoplasma* soon after the diagnosis of HIV infection to detect latent infection with *Toxoplasma gondii* (BIII).

2. All HIV-infected persons, but particularly those who lack IgG antibody to *Toxoplasma*, should be counseled about the various sources of toxoplasmic infection. They should be advised not to eat raw or undercooked meat, particularly undercooked **lamb, beef, pork**, or venison (BIII). Specifically, **lamb, beef, and pork** should be cooked to an internal temperature of **165-170° F** (44); meat cooked until it is no longer pink inside generally has an internal temperature of **165-170° F** and therefore from a more practical perspective, satisfies this requirement. HIV-infected persons should wash their hands after contact with raw meat and after gardening or other contact with soil; in addition, they should wash fruits and vegetables well before eating them raw (BIII). If the patient owns a cat, the litter box should be changed daily, preferably by an HIV-negative, nonpregnant person; alternatively, the patient should wash the hands thoroughly after changing the litter box (BIII). Patients should be encouraged to keep their cats inside and not to adopt or handle stray cats (BIII). Cats should be fed only canned or dried commercial food or well-cooked table food, not raw or undercooked meats (BIII). Patients need not be advised to part with their cats or to have their cats tested for toxoplasmosis (EII).

Prevention of Disease

Initiation of Primary Prophylaxis

3. *Toxoplasma*-seropositive patients who have a CD4+ T-lymphocyte count of less than 100/μL should be administered prophylaxis against toxoplasmic encephalitis (TE) (AII) (25). The double-strength tablet daily dose of TMP-SMZ recommended as the preferred regimen for PCP prophylaxis appears to be effective against TE as well and is therefore recommended (AII) (25). If patients cannot tolerate TMP-SMZ, the recommended alternative is dapsone-pyrimethamine, which is also effective against PCP (BI) (29,30). Atovaquone with or without pyrimethamine also may be considered (CIII). Prophylactic monotherapy with dapsone, pyrimethamine, azithromycin, or clarithromycin cannot be recommended on the basis of current data (DII). Aerosolized pentamidine does not protect against TE and is not recommended (EI) (21,25).

4. *Toxoplasma*-seronegative persons who are not taking a PCP prophylactic regimen known to be active against TE should be retested for IgG antibody to *Toxoplasma* when their CD4+ T-lymphocyte count declines below 100/μL to determine whether they have seroconverted and are therefore at risk for TE (CIII). Patients who have seroconverted should be administered prophylaxis for TE as described above (AII).

Discontinuation of Primary Prophylaxis

5. Prophylaxis against TE should be discontinued in adult and adolescent patients who have responded to HAART with an increase in CD4+ T-lymphocyte counts to > 200 cells/μL for at least 3 months (AI).

Several observational studies (37,41,47) and two randomized trials (38,46) have shown that primary prophylaxis can be discontinued with minimal risk of developing TE in patients who have responded to HAART with an increase in CD4+ T lymphocyte count from < 200 cells/μL to > 200 cells/μL for at least 3 months. In these studies, most patients were taking protease inhibitor-containing regimens and the median CD4+ T-lymphocyte count at the time prophylaxis was discontinued was >300 cells/μL. At the time prophylaxis was discontinued, many patients had sustained suppression of plasma HIV RNA levels below the detection limits of available assays; the median follow up ranged from 7 to 22 months

While patients with CD4+ T lymphocyte counts of <100 cells/μL are at greatest risk for developing TE, the risk of TE occurring when the CD4+ T-lymphocyte count has increased to 100-200 cells/μL has not been studied as rigorously as a rise to >200 cells/μL. Thus, the recommendation specifies discontinuation of prophylaxis after an increase to >200 cells/μL.

Discontinuation of primary TE prophylaxis is recommended not only because prophylaxis appears to add very little to disease prevention for toxoplasmosis, but also because discontinuation of drug reduces pill burden, the potential for drug toxicity, drug interaction, and selection of drug resistant pathogens.

Restarting Primary Prophylaxis

6. Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to <100-200 cells/μL (AIII).

Prevention of Recurrence

7. Patients who have completed initial therapy for TE should be administered lifelong suppressive therapy (secondary prophylaxis or chronic maintenance therapy) (AI) (48,49) unless immune reconstitution occurs as a consequence of HAART (see Recommendation #8 below). The combination of pyrimethamine plus sulfadiazine plus leucovorin is highly effective for this purpose (AI). A commonly used regimen for patients who cannot tolerate sulfa drugs is pyrimethamine plus clindamycin (BI); however, only the combination of pyrimethamine plus sulfadiazine appears to provide protection against PCP as well (AII).

Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)

8. Adult and adolescent patients receiving secondary prophylaxis (chronic maintenance therapy) for TE appear to be at low risk for recurrence of TE when they have successfully completed initial therapy for TE, remain asymptomatic with respect to signs and symptoms of TE, and have a sustained increase in their CD4+ T-lymphocyte counts to >200 cells/μL following HAART (e.g., ≥ 6 months) (41,42,46). While the numbers of patients who have been evaluated remain small and occasional recurrences have been seen, based on these observations and on inference from more extensive cumulative data suggesting the safety of discontinuation of secondary prophylaxis for other OIs during advanced HIV disease, it is reasonable to consider discontinuation of chronic maintenance therapy in such patients (CIII). Some experts would obtain a magnetic resonance image of the brain as part of their evaluation to determine whether or not discontinuation of therapy is appropriate.

Restarting Secondary Prophylaxis

9. Secondary prophylaxis (chronic maintenance therapy) should be reintroduced if the CD4+ T lymphocyte count decreases to <200 cells/μL (AIII).

Special Considerations

Children

10. TMP-SMZ, when administered for PCP prophylaxis, also provides prophylaxis against toxoplasmosis. Atovaquone might also provide protection (CIII). Children aged greater than 12 months who qualify for PCP prophylaxis and who are receiving an agent other than TMP-SMZ or atovaquone should have serologic testing for *Toxoplasma* antibody (BIII), because alternative drugs for PCP prophylaxis might not be effective against *Toxoplasma*. Severely immunosuppressed children who are not receiving TMP-SMZ or atovaquone who are found to be seropositive for *Toxoplasma* should be administered prophylaxis for both PCP and toxoplasmosis (i.e., dapsone plus pyrimethamine) (BIII). **Children with a history of toxoplasmosis should be administered lifelong prophylaxis to prevent recurrence (AI). The safety of discontinuing primary or secondary prophylaxis in HIV-infected children receiving HAART has not been studied extensively.**

Pregnant Women

11. TMP-SMZ can be administered for prophylaxis against TE as described for PCP (AIII). However, because of the low incidence of TE during pregnancy and the possible risk associated with pyrimethamine treatment, chemoprophylaxis with pyrimethamine-containing regimens can reasonably be deferred until after pregnancy (CIII). For prophylaxis against recurrent TE, the health-care provider and clinician should be well informed about the benefit of lifelong therapy and the concerns about teratogenicity of pyrimethamine. **Guidelines outlined in 7-9 above should be used when making decisions regarding secondary prophylaxis for TE in pregnancy.**

12. In rare cases, HIV-infected pregnant women who have serologic evidence of remote toxoplasmic infection have transmitted *Toxoplasma* to the fetus in utero. Pregnant HIV-infected women who have evidence of primary toxoplasmic infection or active toxoplasmosis (including TE) should be evaluated and managed during pregnancy in consultation with appropriate specialists (BIII). Infants born to women who have serologic evidence of infections with HIV and *Toxoplasma* should be evaluated for congenital toxoplasmosis (BIII).

Cryptosporidiosis

Prevention of Exposure

1. HIV-infected persons should be educated and counseled about the many ways that *Cryptosporidium* can be transmitted (BIII). Modes of transmission include having direct contact with infected adults, diaper-aged children, and infected animals; drinking contaminated water; coming into contact with contaminated water during recreational activities; and eating contaminated food.

2. HIV-infected persons should avoid contact with human and animal feces. They should be advised to wash their hands after contact with human feces (e.g., diaper changing), after handling pets, and after gardening or other contact with soil. HIV-infected persons should avoid sexual practices that might result in oral exposure to feces (e.g., oral-anal contact) (BIII).

3. HIV-infected persons should be advised that newborn and very young pets might pose a small risk for transmitting cryptosporidial infection, but they should not be advised to destroy or give away healthy pets. Persons contemplating the acquisition of a new pet should avoid bringing any animal that has diarrhea into their households, should avoid purchasing a dog or cat aged less than 6 months, and should not adopt stray pets. HIV-infected persons who wish to assume the small risk for acquiring a puppy or kitten aged less than 6 months should request that their veterinarian examine the animal's stool for *Cryptosporidium* before they have contact with the animal (BIII).

4. HIV-infected persons should avoid exposure to calves and lambs and to premises where these animals are raised (BII).

5. HIV-infected persons should not drink water directly from lakes or rivers (AIII).

6. Waterborne infection also might result from swallowing water during recreational activities. HIV-infected persons should be aware that many lakes, rivers, and salt-water beaches and some swimming pools, recreational water parks, and ornamental water fountains might be contaminated with human or animal waste that contains *Cryptosporidium*. They should avoid swimming in water that is likely to be contaminated and should avoid swallowing water while swimming or playing in recreational waters (BIII).

7. Several outbreaks of cryptosporidiosis have been linked to municipal water supplies. During outbreaks or in other situations in which a community "boil-water" advisory is issued, boiling water for 1 minute will eliminate the risk for cryptosporidiosis (AI). Use of submicron personal-use water filters* (home/office types) and/or bottled water** also might reduce the risk (CIII). The magnitude of the risk for acquiring cryptosporidiosis from drinking water in a non-outbreak setting is uncertain, and current data are inadequate to recommend that all HIV-infected persons boil water or avoid drinking tap water in non-outbreak settings. However, HIV-infected persons who wish to take independent action to reduce the risk for waterborne cryptosporidiosis may choose to take precautions similar to those recommended during outbreaks. Such decisions should be made in conjunction with health-care providers. Persons who opt for a personal-use filter or bottled water should be aware of the complexities involved in selecting appropriate products, the lack of enforceable standards for the destruction or removal of oocysts, the cost of the products, and the logistic difficulty of using these products consistently.

8. Patients who take precautions to avoid acquiring cryptosporidiosis from drinking water should be advised that ice made from contaminated tap water also can be a source of infection (BII). Such persons also should be aware that fountain beverages served in restaurants, bars, theaters, and other places also might pose a risk because these beverages, as well as the ice they contain, are made from tap water. Nationally distributed brands of bottled or canned carbonated soft drinks are safe to drink. Commercially packaged non-carbonated soft drinks and fruit juices that do not require refrigeration until after they are opened (i.e., those that can be stored unrefrigerated on grocery shelves) also are safe. Nationally distributed brands of frozen fruit juice concentrate are safe if they are reconstituted by the user with water from a safe source. Fruit juices that must be kept refrigerated from the time they are processed to the time of consumption might be either fresh (unpasteurized) or heat-treated (pasteurized); only those juices labeled as pasteurized

should be considered free of risk from *Cryptosporidium*. Other pasteurized beverages and beers also are considered safe to drink (BII). No data are available concerning survival of *Cryptosporidium* oocysts in wine.

9. HIV-infected persons should avoid eating raw oysters because cryptosporidial oocysts can survive in oysters for more than 2 months and have been found in oysters taken from some commercial oyster beds (BIII). *Cryptosporidium*-infected patients should not work as food handlers, especially if the food to be handled is intended to be eaten without cooking (BII). Because most food-borne outbreaks of cryptosporidiosis are believed to have been caused by infected food handlers, more specific recommendations to avoid exposure to contaminated food cannot be made.

10. In a hospital, standard precautions (i.e., use of gloves and hand washing after removal of gloves) should be sufficient to prevent transmission of cryptosporidiosis from an infected patient to a susceptible HIV-infected person (BII). However, because of the potential for fomite transmission, some experts recommend that HIV-infected persons, especially those who are severely immunocompromised, should not share a room with a patient with cryptosporidiosis (CIII).

Prevention of Disease

11. **Rifabutin or clarithromycin, when taken for *Mycobacterium avium* complex prophylaxis, have been found to protect against cryptosporidiosis (50, 51). However, data are insufficient at this time to warrant a recommendation for using these drugs as chemoprophylaxis for cryptosporidiosis.**

Prevention of Recurrence

12. No drug regimens are known to be effective in preventing the recurrence of cryptosporidiosis.

Special Considerations

Children

13. At present, no data indicate that formula-preparation practices for infants should be altered in an effort to prevent cryptosporidiosis (CIII). However, in the event of a "boil-water" advisory, similar precautions for the preparation of infant formula should be taken as for drinking water for adults (AII).

Microsporidiosis

Prevention of Exposure

1. Other than general attention to hand washing and other personal hygiene measures, no precautions to reduce exposure can be recommended at this time.

Prevention of Disease

2. No chemoprophylactic regimens are known to be effective in preventing microsporidiosis.

Prevention of Recurrence

3. No chemotherapeutic regimens are known to be effective in preventing the recurrence of microsporidiosis.

*Only filters capable of removing particles 1 µm in diameter should be considered. Filters that provide the greatest assurance of oocyst removal include those that operate by reverse osmosis, those labeled as absolute 1-µm filters, and those labeled as meeting NSF (National Sanitation Foundation) standard no. 53 for cyst removal. The nominal 1-µm filter rating is not standardized, and many filters in this category might not be capable of removing 99% of oocysts. For a list of filters certified as meeting NSF standards, consult the International Consumer Line at 800-673-8010 or <http://www.nsf.org/notice/crypto.html>.

**Sources of bottled water (e.g., wells, springs, municipal tap-water supplies, rivers, and lakes) and methods for its disinfection differ; therefore, all brands should not be presumed to be free of cryptosporidial oocysts. Water from wells and springs is much less likely to be contaminated by oocysts than water from rivers or lakes. Treatment of bottled water by distillation or reverse osmosis ensures oocyst removal. Water passed through an absolute 1-µm filter or a filter labeled as meeting NSF standard no. 53 for cyst removal before bottling will provide nearly the same level of protection. Use of nominal 1-µm filters by bottlers as the only barrier to *Cryptosporidia* might not result in the removal of 99% of oocysts. For more information, the International Bottled Water Association can be contacted at 703-683-5213 or at <http://bottledwater.org>.

Tuberculosis

Prevention of Exposure

1. HIV-infected persons should be advised that certain activities and occupations might increase the likelihood of exposure to tuberculosis (BIII). These include volunteer work or employment in health-care facilities, correctional institutions, and shelters for the homeless, as well as in other settings identified as high risk by local health authorities. Decisions about whether to continue with activities in these settings should be made in conjunction with the health-care provider and should be based on factors such as the patient's specific duties in the workplace, the prevalence of tuberculosis in the community, and the degree to which precautions are taken to prevent the transmission of tuberculosis in the workplace (BIII). Whether the patient continues with such activities might affect the frequency with which screening for tuberculosis needs to be conducted.

Prevention of Disease

2. When HIV infection is first recognized, the patient should receive a tuberculin skin test (TST) by administration of intermediate-strength (5-TU) purified protein derivative (PPD) by the Mantoux method (AI). Routine evaluation for anergy is not recommended. However, there are selected situations in which anergy evaluation might assist in guiding individual decisions about preventive therapy (52,53).
3. All HIV-infected persons who have a positive TST result (greater than or equal to 5 mm of induration) should undergo chest radiography and clinical evaluation to rule out active tuberculosis. HIV-infected persons who have symptoms suggestive of tuberculosis should promptly undergo chest radiography and clinical evaluation regardless of their TST status (AII).
4. All HIV-infected persons, regardless of age, who have a positive TST result yet have no evidence of active tuberculosis and no history of treatment for active or latent tuberculosis should be treated for latent TB **infection. Options include isoniazid daily (AII) or twice weekly (BII) for 9 months; 4 months of therapy daily with either rifampin (BIII) or rifabutin (CIII); or 2 months of therapy with either rifampin and pyrazinamide (BI) or rifabutin and pyrazinamide (CIII) (52-54). There have been reports of fatal and severe liver injury associated with the treatment of latent TB infection in HIV-uninfected persons treated with the 2 month regimen of daily rifampin and pyrazinamide; therefore it may be prudent to use regimens that do not contain pyrazinamide in HIV-infected persons whose completion of treatment can be assured. (CDC. Update: Fatal and Severe Liver Injuries Associated with Rifampin and Pyrazinamide for Latent Tuberculosis Infection and Revisions in American Thoracic Society/CDC Recommendations, United States 2001 MMWR 50 (No. 34), Aug 31, 2001).** Because HIV-infected persons are at risk for peripheral neuropathy, those receiving isoniazid should also receive pyridoxine (BIII). A decision to use a regimen containing either rifampin or rifabutin should be made after careful consideration of potential drug interactions, especially those related to protease inhibitors and nonnucleoside reverse transcriptase inhibitors (see Special Considerations/Drug Interactions, page 15). Directly observed therapy should be used with intermittent dosing regimens (AI) and when otherwise operationally feasible (BIII) (53).
5. HIV-infected persons who are close contacts of persons who have infectious tuberculosis should be treated for latent TB infection -- regardless of their TST results, age, or prior courses of treatment -- after the diagnosis of active tuberculosis has been excluded (AII) (52-54). In addition to household contacts, such persons might also include contacts in the same drug-treatment or health-care facility, coworkers, and other contacts if transmission of TB is demonstrated.
6. For persons exposed to isoniazid- and/or rifampin-resistant TB, the decision to use chemoprophylactic antimycobacterial agents other than isoniazid alone, **rifampin or rifabutin alone**, rifampin plus pyrazinamide, or rifabutin plus pyrazinamide should be based on the relative risk for exposure to resistant organisms and should be made in consultation with public health authorities (AII).
7. TST-negative, HIV-infected persons from risk groups or geographic areas with a high prevalence of *Mycobacterium tuberculosis* infection might be at increased risk for primary or reactivation tuberculosis. However, the efficacy of treatment in this group has not been demonstrated. Decisions concerning the use of chemoprophylaxis in these situations must be considered individually.
8. Although the reliability of the TST might diminish as the CD4+ T-lymphocyte count declines, annual repeat testing should be considered for HIV-infected persons who are TST-negative on initial evaluation and who belong to populations in which there is a substantial risk for exposure to *M. tuberculosis* (BIII). **Clinicians should consider repeating the TST for persons whose initial skin test was negative and whose immune function has improved in response to HAART (i.e., those whose CD4+ T-lymphocyte count has increased to greater than 200 cells/ μ L) (BIII) (52).** In addition to confirming tuberculous infection, TST conversion in an HIV-infected person should alert health-care providers to the possibility of recent *M. tuberculosis* transmission and should prompt notification of public health officials for investigation to identify a possible source case.
9. The administration of bacille Calmette-Guerin (BCG) vaccine to HIV-infected persons is contraindicated because of its potential to cause disseminated disease (EII).

Prevention of Recurrence

10. Chronic suppressive therapy for a patient who has successfully completed a recommended regimen of treatment for tuberculosis is not necessary (DII).

Special Considerations

Drug Interactions

11. Rifampin can induce metabolism of all the protease inhibitors and nonnucleoside reverse transcriptase inhibitors. This can result in more rapid drug clearance and possibly subtherapeutic drug concentrations of most of these antiretroviral agents. Rifampin should not be co-administered with the following protease inhibitors and nonnucleoside reverse transcriptase inhibitors: amprenavir, indinavir, lopinavir/ritonavir, nelfinavir, saquinavir, and delavirdine (53). However, it may be used with ritonavir, ritonavir plus saquinavir, efavirenz, and possibly with nevirapine. Rifabutin is an acceptable alternative to rifampin but should not be used with the protease inhibitor hard-gel saquinavir or delavirdine; caution is advised if the drug is coadministered with soft-gel saquinavir, because data are sparse. Rifabutin can be administered at one-half the usual daily dose, i.e., reduce from 300 mg to 150 mg per day, with indinavir, nelfinavir, or amprenavir or with one-fourth the usual dose, i.e., 150 mg every other day or three times a week, with ritonavir, ritonavir plus saquinavir, or lopinavir/ritonavir. When rifabutin is administered with indinavir as the sole protease inhibitor, the dose of indinavir should be increased from 800 mg every eight hours to 1,000 mg every eight hours. Pharmacokinetic data suggest that rifabutin at an increased dose can be administered with efavirenz; doses of 450-600 mg per day have been suggested (54). However, little information is available about appropriate dosing if a protease inhibitor is used concurrently with efavirenz and rifabutin; with such a combination the rifabutin dose might need to be reduced. Rifabutin can be used without dose adjustment with nevirapine.

Children

12. Infants born to HIV-infected mothers should have a TST (5-TU PPD) at or before the age of 9-12 months and should be retested at least once a year (AIII). HIV-infected children living in households with TST-positive persons should be evaluated for tuberculosis (AIII); children exposed to a person who has active tuberculosis should be administered preventive therapy after active tuberculosis has been excluded, regardless of their TST results (AII).

Pregnant Women

13. Chemoprophylaxis for tuberculosis is recommended during pregnancy for HIV-infected patients who have either a positive TST or a history of exposure to active tuberculosis, after active tuberculosis has been excluded (AIII). A chest radiograph should be obtained before treatment and appropriate abdominal/pelvic lead apron shields should be used to minimize radiation exposure to the embryo/fetus. When an HIV-infected person has not been exposed to drug-resistant TB, isoniazid daily or twice weekly is the prophylactic regimen of choice. Because of concerns regarding possible teratogenicity associated with drug exposures during the first trimester, providers may choose to initiate prophylaxis after the first trimester. Preventive therapy with isoniazid should be accompanied by pyridoxine to reduce the risk for neurotoxicity. Experience with rifampin or rifabutin during pregnancy is more limited, but anecdotal experience with rifampin has not been associated with adverse pregnancy outcomes. Pyrazinamide should generally be avoided, particularly in the first trimester because of lack of information concerning fetal effects.

Disseminated Infection with *Mycobacterium avium* Complex

Prevention of Exposure

1. Organisms of the *M. avium* complex (MAC) are common in environmental sources such as food and water. Current information does not support specific recommendations regarding avoidance of exposure.

Prevention of Disease

Initiation of Primary Prophylaxis

2. Adults and adolescents who have HIV infection should receive chemoprophylaxis against disseminated MAC disease if they have a CD4+ T-lymphocyte count of less than 50 cells/ μ L (AI) (55). Clarithromycin (56,57) or azithromycin (58) are the preferred prophylactic agents (AI). The combination of clarithromycin and rifabutin is no more effective than clarithromycin alone for chemoprophylaxis and is associated with a higher rate of adverse effects than either drug alone; this combination should not be used (EI) (58). The combination of azithromycin with rifabutin is more effective than azithromycin alone; however, the additional cost, increased occurrence of adverse effects, potential for drug interactions,

and absence of a difference in survival when compared with azithromycin alone do not warrant a routine recommendation for this regimen (CI) (58). In addition to their preventive activity for MAC disease, clarithromycin and azithromycin each confer protection against respiratory bacterial infections (BII). If clarithromycin or azithromycin cannot be tolerated, rifabutin is an alternative prophylactic agent for MAC disease although rifabutin-associated drug interactions make this agent difficult to use (BI) (54). Tolerance, cost, and drug interactions are among the issues that should be considered in decisions regarding the choice of prophylactic agents for MAC disease. Particular attention to interactions with antiretroviral protease inhibitors and nonnucleoside reverse transcriptase inhibitors is warranted (see Special Considerations/Drug Interactions). Before prophylaxis is initiated, disseminated MAC disease should be ruled out by clinical assessment, which might include obtaining a blood culture for MAC if warranted. Because treatment with rifabutin could result in the development of resistance to rifampin in persons who have active tuberculosis, active tuberculosis should also be excluded before rifabutin is used for prophylaxis.

3. Although the detection of MAC organisms in the respiratory or gastrointestinal tract might predict the development of disseminated MAC infection, no data are available on the efficacy of prophylaxis with clarithromycin, azithromycin, rifabutin, or other drugs in patients with MAC organisms at these sites and a negative blood culture. Therefore, routine screening of respiratory or gastrointestinal specimens for MAC cannot be recommended (DIII).

Discontinuation of Primary Prophylaxis

4. Primary MAC prophylaxis should be discontinued in adult and adolescent patients who have responded to HAART with an increase in CD4+ T lymphocyte count to >100 cells/ μ L for at least 3 months (AI).

Two large randomized, placebo controlled trials and observational data have shown that such patients can discontinue primary prophylaxis with minimal risk of developing MAC (37,59-61). Discontinuation of primary prophylaxis in patients meeting the criteria above is recommended not only because prophylaxis appears to add very little to disease prevention for MAC or for bacterial infections, but also because discontinuation of drug reduces pill burden, the potential for drug toxicity, drug interactions, selection of drug resistant pathogens, and cost.

Restarting Primary Prophylaxis

5. Primary prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to < 50-100 cells/ μ L (AIII).

Prevention of Recurrence

6. Adult and adolescent patients with disseminated MAC should receive lifelong therapy (i.e., secondary prophylaxis or maintenance therapy) (AII), unless immune reconstitution occurs as a consequence of HAART (see Recommendation #7 below). Unless good clinical or laboratory evidence of macrolide resistance exists, the use of a macrolide (clarithromycin or, alternatively, azithromycin) is recommended in combination with ethambutol (AII) with or without rifabutin (CI) (62,63). Treatment of MAC disease with clarithromycin in a dose of 1,000 mg twice a day is associated with a higher mortality rate than has been observed with clarithromycin administered at 500 mg twice a day; thus, the higher dose should not be used (EI) (64,65). Clofazimine has been associated with adverse clinical outcomes in the treatment of MAC disease and should not be used (DII) (66).

Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)

7. Patients appear to be at low risk for recurrence of MAC when they have completed a course of at least 12 months of treatment for MAC, remain asymptomatic with respect to MAC signs and symptoms, and have a sustained increase, e.g., \geq 6 months, in their CD4+ T-lymphocyte counts to >100cells/ μ L following HAART. While the numbers of patients who have been evaluated remain small, and recurrences could occur (41,42,67-69), based on these observations and on inference from more extensive data suggesting the safety of discontinuation of secondary prophylaxis for other OIs during advanced HIV disease, it may be reasonable to consider discontinuation of chronic maintenance therapy in such patients (CIII). Some experts would obtain a blood culture for MAC, even in asymptomatic patients, prior to discontinuation of therapy, to substantiate that disease is no longer active.

Restarting Secondary Prophylaxis

8. Secondary prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to <100 cells/ μ L (AIII).

Special Considerations

Drug Interactions

9. Rifabutin should not be administered to patients receiving certain protease inhibitors and nonnucleoside reverse transcriptase inhibitors because the complex interactions have been incompletely studied, and the clinical implications of those interactions are unclear (16,54) (see Special Considerations: Drug interactions in the Tuberculosis section, above). Protease inhibitors may increase clarithromycin levels, but no recommendation to adjust the dose of either clarithromycin or protease inhibitors can be made on the basis of existing data. Efavirenz can induce metabolism of clarithromycin. This may result in reduced serum concentration of clarithromycin but increased concentration of 14-OH clarithromycin, an active metabolite of clarithromycin. Although the clinical significance of this interaction is not known, the efficacy of clarithromycin in MAC prophylaxis could be reduced because of this interaction. Azithromycin pharmacokinetics are not affected by the cytochrome P450 system; azithromycin can be used safely in the presence of protease inhibitors and/or nonnucleoside reverse transcriptase inhibitors without concerns of drug interactions.

Children

10. HIV-infected children aged less than 13 years who have advanced immunosuppression also can develop disseminated MAC infections, and prophylaxis should be offered to high-risk children according to the following CD4+ T-lymphocyte thresholds: children aged greater than or equal to 6 years, less than 50 cells/ μ L; children aged 2-6 years, less than 75 cells/ μ L; children aged 1-2 years, less than 500 cells/ μ L; and children aged less than 12 months, less than 750 cells/ μ L (AII). For the same reasons that clarithromycin and azithromycin are the preferred prophylactic agents for adults, they should also be considered for children (AII); oral suspensions of both agents are commercially available in the United States. No liquid formulation of rifabutin suitable for pediatric use is commercially available in the United States. **Children with a history of disseminated MAC should be administered lifelong prophylaxis to prevent recurrence (AII). The safety of discontinuing MAC prophylaxis in children whose CD4+ T-lymphocyte counts have increased in response to HAART has not been studied.**

Pregnant Women

11. Chemoprophylaxis for MAC disease should be administered to pregnant women as is done for other adults and adolescents (AIII). However, because of general concerns about administering drugs during the first trimester of pregnancy, some providers may choose to withhold prophylaxis during the first trimester. Animal studies and anecdotal evidence of safety in humans suggest that of the available agents, azithromycin is the drug of choice (BIII) (70). Experience with rifabutin is limited. Clarithromycin has been demonstrated to be a teratogen in animals and should be used with caution during pregnancy (71). For secondary prophylaxis (chronic maintenance therapy), azithromycin plus ethambutol are the preferred drugs (BIII) (70).

Bacterial Respiratory Infections

Prevention of Exposure

1. Because *Streptococcus pneumoniae* and *Haemophilus influenzae* are common in the community, no effective way exists to reduce exposure to these bacteria.

Prevention of Disease

2. **Adults and adolescents who have a CD4+ T-lymphocyte count of greater than or equal to 200 cells/ μ L should be administered a single dose of 23-valent polysaccharide pneumococcal vaccine if they have not received this vaccine during the previous five years (BII) (72-76). One randomized placebo-controlled trial of pneumococcal vaccine in Africa paradoxically found an increase in pneumonia among vaccinated subjects (77). However, several observational studies in the United States have not identified increased risk associated with vaccination and have identified benefit in this group (72-76). Most experts believe that the potential benefit of pneumococcal vaccination in the United States outweighs the risk. Immunization should also be considered for patients with CD4+ T lymphocyte counts < 200 cells/ μ L, although there is no clinical evidence for efficacy (CIII). Revaccination may be considered for patients who were initially immunized when their CD4+ T lymphocyte**

count was <200 cells/ μ L and whose CD4+ count has increased to > 200 cells/ μ L in response to HAART (CIII). The recommendation to vaccinate is increasingly pertinent because of the increasing incidence of invasive infections with drug-resistant (including TMP-SMZ-, macrolide-, and beta-lactam-resistant) strains of *S. pneumoniae*.

3. The duration of the protective effect of primary pneumococcal vaccination is unknown. Periodic revaccination may be considered; an interval of 5 years has been recommended for persons not infected with HIV and also might be appropriate for persons infected with HIV (CIII) (75). **There is, however, no evidence for clinical benefit from revaccination.**

4. The incidence of *H. influenzae* type B infection in adults is low. Therefore, *H. influenzae* type B vaccine is not generally recommended for adult use (DIII).

5. TMP-SMZ, when administered daily for PCP prophylaxis, reduces the frequency of bacterial respiratory infections. This should be considered in the selection of an agent for PCP prophylaxis (AII). However, indiscriminate use of this drug (when not indicated for PCP prophylaxis or other specific reasons) might promote the development of TMP-SMZ-resistant organisms. Thus, TMP-SMZ should not be prescribed solely to prevent bacterial respiratory infection (DIII). Similarly, clarithromycin administered daily and azithromycin administered weekly for MAC prophylaxis might be effective in preventing bacterial respiratory infections; this should be considered in the selection of an agent for prophylaxis against MAC disease (BII). However, these drugs should not be prescribed solely for preventing bacterial respiratory infection (DIII).

6. An absolute neutrophil count that is depressed because of HIV disease or drug therapy is associated with an increased risk for bacterial infections, including pneumonia. To reduce the risk for such bacterial infections, providers may consider taking steps to reverse neutropenia, either by stopping myelosuppressive drugs (CII) or by administering granulocyte-colony-stimulating factor (G-CSF) (CII).

Prevention of Recurrence

7. Some clinicians may administer antibiotic chemoprophylaxis to HIV-infected patients who have very frequent recurrences of serious bacterial respiratory infections (CIII). TMP-SMZ, administered for PCP prophylaxis, and clarithromycin or azithromycin, administered for MAC prophylaxis, are appropriate for drug-sensitive organisms. However, providers should be cautious about using antibiotics solely for preventing the recurrence of serious bacterial respiratory infections because of the potential development of drug-resistant microorganisms and drug toxicity.

Special Considerations

Children

8. HIV infected children, less than five years old should be administered *H. influenzae* type b vaccine (AII) and pneumococcal conjugate vaccine (78-80) (BII) in accordance with the guidelines of the Advisory Committee on Immunization Practices (73,75,78) and the American Academy of Pediatrics (79). Children aged greater than 2 years should also receive the 23-valent polysaccharide pneumococcal vaccine (BII). Revaccination with a second dose of the 23 valent polysaccharide pneumococcal vaccine should generally be offered after 3-5 years to children aged less than or equal to 10 years and after 5 years to children aged greater than 10 years (BIII).

9. To prevent serious bacterial infections in HIV-infected children who have hypogammaglobulinemia (IgG less than 400 mg/dL), clinicians should use intravenous immunoglobulin (IVIG) (AI). Respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted for IVIG during the RSV season to provide broad anti-infective protection, if RSV IVIG is available.

10. To prevent recurrence of serious bacterial respiratory infections, antibiotic chemoprophylaxis may be considered (BI). However, providers should be cautious about using antibiotics solely for this purpose because of the potential development of drug-resistant microorganisms and drug toxicity. The administration of IVIG should also be considered for HIV-infected children who have recurrent serious bacterial infections (BI), although such treatment might not provide additional benefit to children who are being administered daily TMP-SMZ. However, IVIG may be considered for children who have recurrent serious bacterial infections despite receiving TMP-SMZ or other antimicrobials (CIII) (81).

Pregnant Women

11. Pneumococcal vaccination is recommended during pregnancy for HIV-infected patients who have not been vaccinated during the previous 5 years (BIII). Among nonpregnant adults, vaccination has been associated with a transient burst of HIV replication. Whether the transient viremia can increase the risk for perinatal HIV transmission is unknown. Because of this concern, when feasible, vaccination may be deferred until after HAART has been initiated to prevent perinatal HIV transmission (CIII).

Bacterial Enteric Infections

Prevention of Exposure

Food

1. Health-care providers should advise HIV-infected persons not to eat raw or undercooked eggs (including foods that might contain raw eggs [e.g., some preparations of hollandaise sauce, Caesar and certain other salad dressings, **some mayonnaises, uncooked cookie and cake batter, egg nog**]); raw or undercooked poultry, meat, seafood (**especially raw shellfish**); unpasteurized dairy products; **unpasteurized fruit juices; and raw seed sprouts (e.g., alfalfa sprouts, mung bean sprouts)**. Poultry and meat are safest when adequate cooking is confirmed with a thermometer (internal temperature of 180° F for poultry and 165 ° F for red meats). If a thermometer is not used, the risk of illness is decreased by consuming poultry and meat that have no trace of pink color. Color change of the meat (e.g., absence of pink) does not always correlate with internal temperature. (BIII). Produce should be washed thoroughly before being eaten (BIII).
2. Health-care providers should advise HIV-infected persons to avoid cross-contamination of foods. Uncooked meats, (including hot dogs) and their juices should not come into contact with other foods. Hands, cutting boards, counters, knives, and other utensils should be washed thoroughly after contact with uncooked foods (BIII).
3. Health-care providers should advise HIV-infected persons that, although the incidence of listeriosis is low, it is a serious disease that occurs with unusually high frequency among severely immunosuppressed HIV-infected persons. An immunosuppressed, HIV-infected person who wishes to reduce the risk of acquiring listeriosis as much as possible may choose to do the following (CIII):
 - a) avoid soft cheeses (e.g., feta, Brie, Camembert, blue-veined and Mexican-style cheese such as queso fresco). Hard cheeses, processed cheeses, cream cheese (including slices and spreads), cottage cheese, or yogurt need not be avoided;
 - b) cook leftover foods or ready-to-eat foods (e.g., hot dogs) until steaming hot before eating;
 - c) avoid foods from delicatessen counters (e.g., prepared salads, meats, cheeses) or heat/reheat these foods until steaming before eating;
 - d) avoid refrigerated pates and other meat spreads, or heat/reheat these foods until steaming. Canned or shelf-stable pate and meat spreads need not be avoided;
 - e) avoid raw or unpasteurized milk (including goat's milk) or milk-products, or foods which contain unpasteurized milk or milk-products. (CIII).

Pets

4. When obtaining a new pet, HIV-infected persons should avoid animals aged less than 6 months, especially those that have diarrhea (BIII).
5. HIV-infected persons should avoid contact with animals that have diarrhea (BIII). HIV-infected pet owners should seek veterinary care for animals with diarrheal illness, and a fecal sample from such animals should be examined for *Cryptosporidium*, *Salmonella*, and *Campylobacter*.
6. HIV-infected persons should wash their hands after handling pets (especially before eating) and should avoid contact with pets' feces (BIII).
7. HIV-infected persons should avoid contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) **as well as chicks and ducklings** because of the risk for salmonellosis (BIII).

Travel

8. The risk for food-borne and waterborne infections among immunosuppressed, HIV-infected persons is magnified during travel to developing countries. Persons who travel to such countries should avoid foods and beverages that might be contaminated, particularly raw fruits and vegetables, raw or undercooked seafood or meat, tap water, ice made with tap water, unpasteurized milk and dairy products, and items sold by street vendors (AII). Foods and beverages that are generally safe include steaming-hot foods, fruits that are peeled by the traveler, bottled (especially carbonated) beverages, hot coffee and tea, beer, wine, and water brought to a rolling boil for 1 minute (AII). Treatment of water with iodine or chlorine might not be as effective as boiling but can be used when boiling is not practical (BIII).

Prevention of Disease

9. Prophylactic antimicrobial agents are not generally recommended for travelers (DIII). The effectiveness of these agents depends on local antimicrobial-resistance patterns of gastrointestinal pathogens, which are seldom known. Moreover, these agents can elicit adverse reactions and can promote the emergence of resistant organisms. However, for

HIV-infected travelers, antimicrobial prophylaxis may be considered, depending on the level of immunosuppression and the region and duration of travel (CIII). The use of fluoroquinolones such as ciprofloxacin (500 mg per day) can be considered when prophylaxis is deemed necessary (CIII). As an alternative (e.g., for children, pregnant women, and persons already taking TMP-SMZ for PCP prophylaxis), TMP-SMZ might offer some protection against traveler's diarrhea (BIII). The risk of toxicity should be considered before treatment with TMP-SMZ is initiated solely because of travel.

10. Antimicrobial agents such as fluoroquinolones should be given to patients before their departure, to be taken empirically (e.g., 500 mg of ciprofloxacin twice a day for 3-7 days) should significant traveler's diarrhea develop (BIII). Fluoroquinolones should be avoided for children aged less than 18 years and pregnant women, and alternative antibiotics should be considered (BIII). Travelers should consult a physician if their diarrhea is severe and does not respond to empirical therapy, if their stools contain blood, if fever is accompanied by shaking chills, or if dehydration develops. Antiperistaltic agents (e.g., loperamide) can be used to treat mild diarrhea. However, the use of these drugs should be discontinued if symptoms persist beyond 48 hours. Moreover, these agents should not be administered to patients who have a high fever or who have blood in the stool (AII).

11. Some experts recommend that HIV-infected persons who have *Salmonella* gastroenteritis be administered antimicrobial therapy to prevent extraintestinal spread of the pathogen. However, no controlled study has demonstrated a beneficial effect of such treatment, and some studies of immunocompetent persons have suggested that antimicrobial therapy can lengthen the shedding period. The fluoroquinolones -- primarily ciprofloxacin (750 mg twice a day for 14 days) -- can be used when antimicrobial therapy is chosen (CIII).

Prevention of Recurrence

12. HIV-infected persons who have *Salmonella* septicemia require long-term therapy (i.e., secondary prophylaxis or chronic maintenance therapy) to prevent recurrence. Fluoroquinolones, primarily ciprofloxacin, are usually the drugs of choice for susceptible organisms (BII).

13. Household contacts of HIV-infected persons who have salmonellosis or shigellosis should be evaluated for persistent asymptomatic carriage of *Salmonella* or *Shigella* so that strict hygienic measures and/or antimicrobial therapy can be instituted and recurrent transmission to the HIV-infected person can be prevented (CIII).

Special Considerations

Children

14. Like HIV-infected adults, HIV-infected children should wash their hands after handling pets (especially before eating) and should avoid contact with pets' feces. Hand washing should be supervised (BIII).

15. HIV-exposed infants aged less than 3 months and all HIV-infected children who have severe immunosuppression should be administered treatment for *Salmonella* gastroenteritis to prevent extraintestinal spread of the pathogen (CIII). Choices of antibiotics include TMP-SMZ, ampicillin, cefotaxime, ceftriaxone, or chloramphenicol; fluoroquinolones should be used with caution and only if no alternatives exist.

16. HIV-infected children who have *Salmonella* septicemia should be offered long-term therapy to prevent recurrence (CIII). TMP-SMZ is the drug of choice; ampicillin or chloramphenicol can be used if the organism is susceptible.

Fluoroquinolones should be used with caution and only if no alternative exists.

17. Antiperistaltic drugs are not recommended for children (DIII).

Pregnant Women

18. Because both pregnancy and HIV infection confer a risk for listeriosis, pregnant HIV-infected women should heed recommendations regarding listeriosis (BII).

19. Because extraintestinal spread of *Salmonella* during pregnancy might lead to infection of the placenta and amniotic fluid and result in pregnancy loss similar to that seen with *Listeria monocytogenes*, pregnant women with *Salmonella* gastroenteritis should receive treatment (BIII). Choices for treatment include ampicillin, cefotaxime, ceftriaxone, or TMP-SMZ. Fluoroquinolones should be avoided.

20. Fluoroquinolones should not be used during pregnancy. TMP-SMZ might offer some protection against traveler's diarrhea.

Bartonellosis

Prevention of Exposure

1. HIV-infected persons, particularly those who are severely immunosuppressed, are at unusually high risk for developing relatively severe disease due to infection with *Bartonella*, which can be transmitted from cats. These persons should consider the potential risks of cat ownership (CIII). Persons who acquire a cat should adopt or purchase an animal aged greater than 1 year that is in good health (BII).

2. Although declawing is not generally advised, HIV-infected persons should avoid rough play with cats and situations in which scratches are likely (BII). Any cat-associated wound should be washed promptly (CIII). Cats should not be allowed to lick open wounds or cuts of HIV-infected persons (BIII).
3. Care of cats should include flea control (CIII).
4. No evidence indicates any benefits to cats or their owners from routine culture or serologic testing of the pet for Bartonella infection (DII).

Prevention of Disease

5. No data support chemoprophylaxis for Bartonella-associated disease (CIII).

Prevention of Recurrence

6. Relapse or reinfection with Bartonella has sometimes followed a course of primary treatment. Although no firm recommendation can be made regarding prophylaxis in this situation, long-term suppression of infection with erythromycin or doxycycline should be considered (CIII).

Special Considerations

Children

7. The risks of cat ownership for HIV-infected children who are severely immunocompromised should be discussed with parents and caretakers (CIII).

Pregnant Women

8. If long-term suppression of Bartonella infection is required, erythromycin should be used. Tetracycline should not be used during pregnancy.

Candidiasis

Prevention of Exposure

1. *Candida* organisms are common on mucosal surfaces and skin. No measures are available to reduce exposure to these fungi.

Prevention of Disease

2. Data from prospective controlled trials indicate that fluconazole can reduce the risk for mucosal (oropharyngeal, esophageal, and vaginal) candidiasis and cryptococcosis as well in patients with advanced HIV disease (75-77). However, routine primary prophylaxis is not recommended because of the effectiveness of therapy for acute disease, the low mortality associated with mucosal candidiasis, the potential for resistant *Candida* organisms to develop, the possibility of drug interactions, and the cost of prophylaxis (DIII).

Prevention of Recurrence

3. Many experts do not recommend chronic prophylaxis of recurrent oropharyngeal or vulvovaginal candidiasis for the same reasons that they do not recommend primary prophylaxis. However, if recurrences are frequent or severe, providers may consider administering an oral azole (fluconazole [CI] [82-84] or itraconazole solution [CI]). Other factors that influence choices about such therapy include the impact of the recurrences on the patient's well-being and quality of life, the need for prophylaxis for other fungal infections, cost, toxicities, drug interactions, and the potential to induce drug resistance among *Candida* and other fungi. Prolonged use of systemically absorbed azoles, particularly in patients with low CD4+ T-lymphocyte counts (i.e., less than 100 cells/ μ L), increases the risk for the development of azole resistance.
4. Adults or adolescents who have a history of documented esophageal candidiasis, particularly multiple episodes, should be considered candidates for chronic suppressive therapy. Fluconazole at a dose of 100-200 mg daily is appropriate (BI). However, the potential development of azole resistance should be taken into account when long-term azoles are considered.

Special Considerations

Children

5. Primary prophylaxis of candidiasis in HIV-infected infants is not indicated (DIII).
6. Suppressive therapy with systemic azoles should be considered for infants who have severe recurrent mucocutaneous candidiasis (CIII) and particularly for those who have esophageal candidiasis (BIII).

Pregnant Women

7. Experience is limited with the use of systemic antifungal drugs during human pregnancy. Four cases of infants born with craniofacial and skeletal abnormalities following prolonged in utero exposure to fluconazole have been reported (85,86). In addition, itraconazole is embryotoxic and teratogenic in animal systems (87). These same potential risks of teratogenicity are presumed to apply to other systemically absorbed azole antifungals, such as ketoconazole. Therefore, chemoprophylaxis against oropharyngeal, esophageal, or vaginal candidiasis using systemically absorbed azoles should not be initiated during pregnancy (DIII), and azoles should be discontinued for HIV-infected women who become pregnant (DIII). Effective birth control measures should be recommended to all HIV-infected women on azole therapy for candidiasis (AIII).

Cryptococcosis

Prevention of Exposure

1. HIV-infected persons cannot completely avoid exposure to *Cryptococcus neoformans*. No evidence exists that exposure to pigeon droppings is associated with an increased risk for acquiring cryptococcosis.

Prevention of Disease

2. Routine testing of asymptomatic persons for serum cryptococcal antigen is not recommended because of the low probability that the results will affect clinical decisions (DIII).
3. Prospective controlled trials indicate that fluconazole and itraconazole can reduce the frequency of cryptococcal disease among patients who have advanced HIV disease. However, most experts recommend that antifungal prophylaxis not be used routinely to prevent cryptococcosis because of the relative infrequency of cryptococcal disease, the lack of survival benefits associated with prophylaxis, the possibility of drug interactions, the potential development of antifungal drug resistance, and cost. The need for prophylaxis or suppressive therapy for other fungal infections (e.g., candidiasis, histoplasmosis, or coccidioidomycosis) should be considered in making decisions about prophylaxis for cryptococcosis. If used, fluconazole at doses of 100-200 mg daily is reasonable for patients whose CD4+ T-lymphocyte counts are less than 50 cells/ μ L (CI) (82).

Prevention of Recurrence

4. Patients who have completed initial therapy for cryptococcosis should be administered lifelong suppressive treatment, (i.e., secondary prophylaxis or chronic maintenance therapy) (AI) **unless immune reconstitution occurs as a consequence of HAART (see Recommendation #5 below). Fluconazole is superior to itraconazole in preventing relapse of cryptococcal disease and is the preferred drug (AI) (88-90).**

Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)

5. Adult and adolescent patients appear to be at low risk for recurrence of cryptococcosis when they have successfully completed a course of initial therapy for cryptococcosis, remain asymptomatic with respect to signs and symptoms of cryptococcosis, and have a sustained increase (e.g., \geq 6 months) in their CD4+ T-lymphocyte counts to >100 -200 cells/ μ L following HAART. The numbers of patients who have been evaluated remain small (91,92). Based on these observations and on inference from more extensive data suggesting the safety of discontinuation of secondary prophylaxis for other OIs during advanced HIV disease, and while recurrences could occur it may be reasonable to consider discontinuation of chronic maintenance therapy in such patients (CIII). Some experts would perform a lumbar puncture to determine if the CSF is culture negative before stopping therapy even if patients have been asymptomatic; other experts do not believe this is necessary.

Restarting Secondary Prophylaxis

6. Maintenance therapy should be reinitiated if the CD4+ T-lymphocyte count decreases to <100 -200 cells/ μ L (AIII).

Special Considerations

Children

7. No data exist on which to base specific recommendations for children, but lifelong suppressive therapy with fluconazole after an episode of cryptococcosis is appropriate (AIII).

Pregnant Women

8. Prophylaxis with fluconazole or itraconazole should not be initiated during pregnancy because of the low incidence of cryptococcal disease, the lack of a recommendation for primary prophylaxis against cryptococcosis in nonpregnant adults, and potential teratogenic effects of these drugs during pregnancy (DIII) (85,86). For patients who conceive while being administered primary prophylaxis and who elect to continue their pregnancy, prophylaxis should be discontinued. The occurrence of craniofacial and skeletal abnormalities in infants following prolonged in utero exposure to fluconazole should be considered when assessing the therapeutic options for HIV-infected women who become pregnant and are receiving secondary prophylaxis (chronic maintenance therapy) for cryptococcosis (85,86). **If a woman meets the criteria for discontinuation of secondary prophylaxis as discussed above, strong consideration should be given to discontinuing therapy during pregnancy as long as the CD4+ T lymphocyte count remains above 100-200 cells/ μ L.** For patients requiring therapy, amphotericin B may be preferred, especially during the first trimester. Effective birth control measures should be recommended to all HIV-infected women on azole therapy for cryptococcosis (AIII).

Histoplasmosis

Prevention of Exposure

1. Although HIV-infected persons living in or visiting histoplasmosis-endemic areas cannot completely avoid exposure to *Histoplasma capsulatum*, those whose CD4+ T-lymphocyte counts are less than 200 cells/ μ L should avoid activities known to be associated with increased risk (e.g., creating dust when working with surface soil; cleaning chicken coops that are heavily contaminated with droppings; disturbing soil beneath bird-roosting sites; cleaning, remodeling, or demolishing old buildings; and exploring caves) (CIII).

Prevention of Disease

2. Routine skin testing with histoplasmin and serologic testing for antibody or antigen in histoplasmosis-endemic areas are not predictive of disease and should not be performed (DII).

3. Data from a prospective randomized controlled trial indicate that itraconazole can reduce the frequency of histoplasmosis among patients who have advanced HIV infection and who live in *H. capsulatum*-endemic areas (93). However, no survival benefit was observed among persons receiving itraconazole. Prophylaxis with itraconazole may be considered in patients with CD4+ T-lymphocyte counts less than 100 cells/ μ L who are at especially high risk because of occupational exposure or who live in a community with a hyperendemic rate of histoplasmosis (greater than or equal to 10 cases per 100 patient-years) (CI).

Prevention of Recurrence

4. Patients who complete initial therapy for histoplasmosis should be administered lifelong suppressive treatment (i.e., secondary prophylaxis or chronic maintenance therapy) with itraconazole (200 mg twice a day) (AI) (94).

Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)

5. Although patients receiving secondary prophylaxis (chronic maintenance therapy) might be at low risk for recurrence of systemic mycosis when their CD4+ T-lymphocyte counts increase to greater than 100 cells/ μ L, in response to HAART, the numbers of patients who have been evaluated are insufficient to warrant a recommendation to discontinue prophylaxis.

Special Considerations

Children

6. Because primary histoplasmosis can lead to disseminated infection in children, a reasonable option is to administer lifelong suppressive therapy after an acute episode of the disease (AIII).

Pregnant Women

7. Because of the embryotoxicity and teratogenicity of itraconazole in animal systems, primary prophylaxis against histoplasmosis should not be offered during pregnancy (DIII) (80). These data as well as the observation of craniofacial and skeletal abnormalities in infants following prolonged in utero exposure to fluconazole (85,86) should be considered when assessing the need for chronic maintenance therapy in HIV-infected pregnant women with histoplasmosis. For such patients, therapy with amphotericin B may be preferred, especially during the first trimester. **For women receiving HAART with a sustained rise in CD4+ T lymphocyte counts above 100 cells/ μ L, discontinuation of azole prophylaxis, especially during the first trimester, should be considered.** Effective birth control measures should be recommended to all HIV-infected women on azole therapy for histoplasmosis (AIII).

Coccidioidomycosis

Prevention of Exposure

1. Although HIV-infected persons living in or visiting areas in which coccidioidomycosis is endemic cannot completely avoid exposure to *Coccidioides immitis*, they should, when possible, avoid activities associated with increased risk (e.g., those involving extensive exposure to disturbed native soil, for example, at building excavation sites or during dust storms) (CIII).

Prevention of Disease

2. Routine skin testing with coccidioidin (spherulin) in coccidioidomycosis-endemic areas is not predictive of disease and should not be performed (DII). Within the endemic area, a positive serologic test might indicate an increased risk for active infection; however, routine testing does not appear to be useful and should not be performed (DIII).
3. Primary prophylaxis for HIV-infected persons who live in coccidioidomycosis-endemic areas is not routinely recommended.

Prevention of Recurrence

4. Patients who complete initial therapy for coccidioidomycosis should be administered lifelong suppressive therapy (i.e., secondary prophylaxis or chronic maintenance therapy) (AII) using either 400 mg of fluconazole by mouth each day or 200 mg of itraconazole twice a day (95). Patients with meningeal disease require consultation with an expert.

Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)

5. Although patients receiving secondary prophylaxis (chronic maintenance therapy) might be at low risk for recurrence of systemic mycosis when their CD4+ T-lymphocyte counts increase to greater than 100 cells/ μ L, in response to HAART, the numbers of patients who have been evaluated are insufficient to warrant a recommendation to discontinue prophylaxis.

Special Considerations

Children

6. Although no specific data are available regarding coccidioidomycosis in HIV-infected children, a reasonable option is to administer lifelong suppressive therapy after an acute episode of the disease (AIII).

Pregnant Women

7. The potential teratogenicity of fluconazole (85,86) and itraconazole (80) should be considered when assessing the therapeutic options for HIV-infected women who become pregnant while receiving chronic maintenance therapy for coccidioidomycosis. For such patients, therapy with amphotericin B may be preferred, especially during the first trimester. **For women receiving HAART with a sustained rise in CD4+ T lymphocyte counts above 100 cells/ μ L, discontinuation of azole prophylaxis, especially during the first trimester, should be considered.** Effective birth control measures should be recommended for all HIV-infected women on azole therapy for coccidioidomycosis (AIII).

Cytomegalovirus Disease

Prevention of Exposure

1. HIV-infected persons who belong to risk groups with relatively low rates of seropositivity for cytomegalovirus (CMV) and who therefore cannot be presumed to be seropositive should be tested for antibody to CMV (BIII). These groups include patients who have not had male homosexual contact or used injection drugs.
2. HIV-infected adolescents and adults should be advised that CMV is shed in semen, cervical secretions, and saliva and that latex condoms must always be used during sexual contact to reduce the risk for exposure to CMV and to other sexually transmitted pathogens (AII).

3. HIV-infected adults and adolescents who are child-care providers or parents of children in child-care facilities should be informed that they are at increased risk for acquiring CMV infection (BI). Similarly, parents and other caretakers of HIV-infected children should be advised of the increased risk to children at these centers (BIII). The risk for acquiring CMV infection can be diminished by good hygienic practices such as hand washing (AII).
4. HIV-exposed infants and HIV-infected children, adolescents, and adults who are seronegative for CMV and require blood transfusion should be administered only CMV antibody-negative or leukocyte-reduced cellular blood products in nonemergency situations (BIII).

Prevention of Disease

5. Prophylaxis with oral ganciclovir may be considered for HIV-infected adults and adolescents who are CMV seropositive and who have a CD4+ T-lymphocyte count of less than 50 cells/ μ L (CI) (96,97). Ganciclovir-induced neutropenia, anemia, conflicting reports of efficacy, lack of proven survival benefit, the risk for developing ganciclovir-resistant CMV, and cost are among the issues that should be considered when deciding whether to institute prophylaxis in individual patients. Acyclovir is not effective in preventing CMV disease, and valacyclovir is not recommended because of an unexplained trend toward increased deaths among persons with AIDS who were administered valacyclovir for CMV prophylaxis (98). Therefore, neither acyclovir nor valacyclovir should be used for this purpose (EI). The most important method for preventing severe CMV disease is recognition of the early manifestations of the disease. Early recognition of CMV retinitis is most likely when the patient has been educated on this topic. Patients should be made aware of the significance of increased floaters in the eye and should be advised to assess their visual acuity regularly by using simple techniques such as reading newsprint (BIII). Regular funduscopic examinations performed by an ophthalmologist are recommended by some experts for patients with low (e.g., less than 50 cells/ μ L) CD4+ T-lymphocyte counts (CIII).

Prevention of Recurrence

6. CMV disease is not cured with courses of the currently available antiviral agents (e.g., ganciclovir, foscarnet, cidofovir, or fomivirsen). Following induction therapy, secondary prophylaxis (chronic maintenance therapy) is recommended for life (AI), **unless there is immune reconstitution as a consequence of HAART (see recommendation #7 below)**. Regimens demonstrated to be effective for chronic suppression in randomized, controlled clinical trials include parenteral or oral ganciclovir, parenteral foscarnet, combined parenteral ganciclovir and foscarnet, parenteral cidofovir, and (for retinitis only) ganciclovir administration via intraocular implant **or repetitive intravitreal injections of fomivirsen (AI) (99-107)**. **Oral valganciclovir has been approved by the FDA for both acute induction therapy and for maintenance therapy although much of the data have not been published. Repetitive intravitreal injections of ganciclovir, foscarnet, and cidofovir have been reported to be effective for secondary prophylaxis of CMV retinitis in uncontrolled case series (108,109)** Intraocular therapy alone does not provide protection to the contralateral eye or to other organ systems and typically is combined with oral ganciclovir (99). The choice of a chronic maintenance regimen for patients treated for CMV disease should be made in consultation with an expert. For patients with retinitis, this decision should be made in consultation with an ophthalmologist and should take into consideration the anatomic location of the retinal lesion, vision in the contralateral eye, the immunologic and virologic status of the patient, and the patient's response to HAART (BIII).

Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy)

7. **Several case series have reported that maintenance therapy can be discontinued safely in adult and adolescent patients with CMV retinitis whose CD4+ T-lymphocyte counts have shown a sustained (e.g., \geq 6 months) increase to > 100 - 150 cells/ μ L in response to HAART (110-115). These patients have remained disease-free for greater than 30-95 weeks, whereas in the pre-HAART era, retinitis typically reactivated within 6-8 weeks after stopping CMV therapy. Plasma HIV RNA levels were variable in these patients, suggesting that the CD4+ T-lymphocyte count is the primary determinant of immune recovery to CMV. Discontinuation of prophylaxis should be considered in patients with a sustained, (e.g., \geq 6 months) increase in CD4+ T-lymphocyte count to >100 - 150 cells/ μ L in response to HAART (BII). Such decisions should be made in consultation with an ophthalmologist and should take into account such factors as magnitude and duration of CD4+ T-lymphocyte increase, anatomic location of the retinal lesion, vision in the contralateral eye, and the feasibility of regular ophthalmologic monitoring (BII). All patients who have had anti-CMV maintenance therapy discontinued should continue to undergo regular ophthalmologic monitoring for early detection of CMV relapse (as well as for immune reconstitution uveitis) (AIII). CMV viral load or other markers of CMV infection, e.g., antigenemia, or viral DNA tests are not well standardized; their role in predicting relapse remains to be defined (116-117). Relapses have been reported rarely in patients with CD4+ T lymphocyte count >100 - 150 cells/ μ L (118).**

Restarting Secondary Prophylaxis

8. Relapse of CMV retinitis occurs in patients whose anti-CMV maintenance therapy has been discontinued and whose CD4+ T-lymphocyte count has decreased to <50 cells/ μ L (108). Therefore, reinstitution of secondary prophylaxis should be reinstated when the CD4+ T-lymphocyte count has decreased to <100-150 cells/ μ L (AIII). Relapse has been reported in patients whose CD4+ T lymphocyte counts are higher than 100 cells/ μ L, but such reports are rare to date (118).

Special Considerations

Children

9. Some experts recommend obtaining a CMV urine culture on all HIV-infected (or exposed) infants at birth or at an early postnatal visit to identify those infants with congenital CMV infection (CIII). In addition, beginning at 1 year of age, CMV antibody testing on an annual basis may be considered for CMV-seronegative (and culture-negative) HIV-infected infants and children who are severely immunosuppressed (Table 9) (CIII). Annual testing will allow identification of children who have acquired CMV infection and might benefit from screening for retinitis.

10. HIV-infected children who are CMV-infected and severely immunosuppressed might benefit from a dilated retinal examination performed by an ophthalmologist every 4-6 months (CIII). In addition, older children should be counseled to be aware of floaters in the eye, similar to the recommendation for adults (BIII).

11. Oral ganciclovir results in reduced CMV shedding in CMV-infected children and may be considered for primary prophylaxis against CMV disease in CMV-infected children who are severely immunosuppressed (e.g., CD4+ T-lymphocyte count less than 50 cells/ μ L) (CII).

12. Patients with a history of CMV disease should be administered lifelong prophylaxis to prevent recurrence (AII). For children with CMV disease, no data are available to guide decisions concerning discontinuation of secondary prophylaxis (chronic maintenance therapy) when the CD4+ T-lymphocyte count has increased in response to HAART.

Pregnant Women

13. Indications for prophylaxis are the same for pregnant women as for non-pregnant women. The choice of agents to be used in pregnancy should be individualized after consultation with experts.

Herpes Simplex Virus Disease

Prevention of Exposure

1. HIV-infected persons should use latex condoms during every act of sexual intercourse to reduce the risk for exposure to herpes simplex virus (HSV) and to other sexually transmitted pathogens (AII). They should specifically avoid sexual contact when herpetic lesions (genital or orolabial) are evident (AII).

Prevention of Disease

2. Antiviral prophylaxis after exposure to HSV, or to prevent initial episodes of HSV disease in individuals with latent infection is not recommended (DIII).

Prevention of Recurrence

3. Because episodes of HSV disease can be treated successfully, chronic therapy with acyclovir is not required after lesions resolve. However, persons who have frequent or severe recurrences can be administered daily suppressive therapy with oral acyclovir or **oral** famciclovir (AI) (119-120). Valacyclovir also is an option (CIII). Intravenous foscarnet or cidofovir can be used to treat infection due to acyclovir-resistant isolates of HSV, which are routinely resistant to ganciclovir as well (AII).

Special Considerations

Children

4. The recommendations for preventing initial disease and recurrence among adults and adolescents apply to children as well.

Pregnant Women

5. Oral acyclovir prophylaxis during late pregnancy is a controversial strategy recommended by some experts to prevent neonatal herpes transmission. However, such prophylaxis is not routinely recommended. For patients who have frequent, severe recurrences of genital HSV disease, acyclovir prophylaxis might be indicated (BIII). No pattern of adverse pregnancy outcomes has been reported after acyclovir exposures (121).

Varicella-Zoster Virus Disease

Prevention of Exposure

1. HIV-infected children and adults who are susceptible to varicella-zoster virus (VZV) (i.e., those who have no history of chickenpox or shingles or are seronegative for VZV) should avoid exposure to persons with chickenpox or shingles (AII). Household contacts (especially children) of susceptible HIV-infected persons should be vaccinated against VZV if they have no history of chickenpox and are seronegative for HIV, so that they will not transmit VZV to their susceptible HIV-infected contacts (BIII).

Prevention of Disease

2. Very little data regarding the safety and efficacy of varicella vaccine in HIV-infected adults are available, and no recommendation for its use can be made for this population. (See Special Considerations/Children, below, for information about the use of varicella vaccine in children.)
3. For the prophylaxis of chickenpox, HIV-infected children and adults who are susceptible to VZV (i.e., those who have no history of chickenpox or shingles or who have no detectable antibody against VZV) should be administered varicella zoster immune globulin (VZIG) as soon as possible but within 96 hours after close contact with a patient who has chickenpox or shingles (AIII). Data are lacking on the effectiveness of acyclovir for preventing chickenpox in susceptible HIV-infected children or adults.
4. No preventive measures are currently available for shingles.

Prevention of Recurrence

5. No drug has been proven to prevent the recurrence of shingles in HIV-infected persons.

Special Considerations

Children

6. HIV-infected children who are asymptomatic and not immunosuppressed (i.e., in immunologic category 1, [Table 9](#)) should receive live attenuated varicella vaccine at 12-15 months of age or later (BII). Varicella vaccine should not be administered to other HIV-infected children because of the potential for disseminated viral infection (EIII).

Pregnant Women

7. VZIG is recommended for VZV-susceptible, HIV-infected pregnant women within 96 hours after exposure to VZV (AIII). If oral acyclovir is used, VZV serology should be performed so that the drug can be discontinued if the patient is seropositive for VZV (BIII).

Human Herpesvirus 8 Infection (Kaposi's Sarcoma-Associated Herpes Virus)

Prevention of Exposure

1. Persons co-infected with HIV and HHV-8 are at risk for developing Kaposi's sarcoma (KS), and, there is evidence that progression to KS may be accelerated in individuals who seroconvert to HHV-8 after being infected with HIV. Thus it is important to prevent acquisition of HHV-8 infections in those already infected with HIV (122-124). The three major routes of HHV-8 transmission appear to be oral (the virus infects oral epithelial cells, and infection has been associated with deep kissing in one study), via semen (HHV-8 is less frequently detected in semen than in saliva), and through blood via needle sharing (125-127). Patients should be counseled that deep kissing and sexual intercourse with individuals who have high risk of being infected with HHV-8, e.g., persons who have KS or who are infected with HIV, may lead to acquisition of the agent that causes KS (CIII). Although the efficacy of condom use for preventing HHV-8 exposure has not been established, HIV-infected persons should use latex condoms during every act of sexual intercourse to reduce exposure to sexually transmitted pathogens

(AII). HIV-infected injection drug users should be counseled to not share drug injection equipment, even if both users are already HIV-infected, because of the chance of becoming infected with HHV-8 or other bloodborne pathogens (BIII).

Prevention of Disease

2. Because clinical use of routine serologic testing to identify HHV-8 infection has not been established, no recommendation for serologic testing can be made at this time.
3. Lower rates of KS have been observed among AIDS patients treated with ganciclovir or foscarnet for CMV retinitis (98). HHV-8 replication in vitro is inhibited by ganciclovir, foscarnet, and cidofovir. However, because the efficacy and clinical use of these drugs in preventing KS have not been established, no recommendation can be made concerning the use of these or other drugs to prevent KS in individuals coinfecting with HIV and HHV-8.
4. Potent antiretroviral drug combinations that suppress HIV replication reduce the frequency of KS in HIV-infected persons (128) and should be considered for all persons who qualify for such therapy (BII).

Prevention of Recurrence

5. Effective suppression of HIV replication with antiretroviral drugs in HIV-infected patients with KS might prevent KS progression or the development of new lesions and should be considered for all persons with KS (BII).

Special Considerations

Children

6. In parts of the world where HHV-8 is endemic, mother-to-child transmission of HHV-8 has been reported and (129-132) horizontal transmission among young children, possibly via saliva occurs. However, no recommendations are currently available for preventing HHV-8 transmission from child to child.

Human Papillomavirus Infection

Prevention of Exposure

1. HIV-infected persons should use latex condoms during every act of sexual intercourse to reduce the risk for exposure to sexually transmitted pathogens (AII), although little evidence exists to suggest that condoms reduce the risk for infection with human papillomavirus (HPV).

Prevention of Disease

HPV-associated Genital Epithelial Cancers in HIV-infected Women

2. After a complete history of previous cervical disease has been obtained, HIV-infected women should have a pelvic examination and a Pap smear. In accordance with the recommendation of the Agency for Health Care Policy and Research, the Pap smear should be obtained twice in the first year after diagnosis of HIV infection and, if the results are normal, annually thereafter (AII).
3. If the results of the Pap smear are abnormal, care should be provided according to the *Interim Guidelines for Management of Abnormal Cervical Cytology* published by a National Cancer Institute Consensus Panel and briefly summarized in Recommendations 4-8, which follow (133).
4. For patients whose Pap smears are interpreted as atypical squamous cells of undetermined significance (ASCUS), several management options are available; the choice depends in part on whether the interpretation of ASCUS is qualified by a statement indicating that a neoplastic process is suspected. Follow-up by Pap tests without colposcopy is acceptable, particularly when the diagnosis of ASCUS is not qualified further or the cytopathologist suspects a reactive process. In such situations, Pap tests should be repeated every 4-6 months for 2 years until three consecutive smears have been negative. If a second report of ASCUS occurs in the 2-year follow-up period, the patient should be considered for colposcopic evaluation (BIII).
5. Women who have a diagnosis of unqualified ASCUS associated with severe inflammation should be evaluated for an infectious process. If specific infections are identified, reevaluation should be performed after appropriate treatment, preferably after 2-3 months (BIII).
6. If the diagnosis of ASCUS is qualified by a statement indicating that a neoplastic process is suspected, the patient should be managed as if a low-grade squamous intraepithelial lesion (LSIL) were present (see Recommendation 7, which follows) (BIII). If a patient who has a diagnosis of ASCUS is at high risk (i.e., previous positive Pap tests or poor adherence to follow-up), the option of colposcopy should be considered (BIII).
7. Several management options are available for patients who have LSIL. Follow up with Pap tests every 4-6 months is used by many clinicians and is currently used in countries outside the United States as an established method of

management. Patients managed in this way must be carefully selected and considered reliable for follow-up. If repeat smears show persistent abnormalities, colposcopy and directed biopsy are indicated (BIII). Colposcopy and directed biopsy of any abnormal area on the ectocervix constitute another appropriate option (BIII).

8. Women who have cytologic diagnosis of high-grade squamous intraepithelial lesions (HSILs) or squamous cell carcinoma should undergo colposcopy and directed biopsy (AII).

9. No data are available to suggest that these guidelines to prevent cervical disease should be modified for women on HAART.

HPV-associated Anal Intraepithelial Neoplasia and Anal Cancer in HIV-infected Men Who Have Sex With Men and in Women

10. Evidence from several studies shows that HPV-positive men who have sex with men and HPV infected women are at increased risk for anal HSILs and might be at increased risk for anal cancer. In view of this evidence, coupled with a recent cost-effectiveness analysis projecting that screening and treatment for anal HSILs provide clinical benefits comparable to other measures to prevent OIs in HIV-infected persons (130), anal cytology screening of HIV-infected men who have sex with men and women might become a useful preventive measure in the near future. However, further studies of screening and treatment programs for anal HSILs need to be carried out before recommendations for routine anal cytology screening can be made.

Prevention of Recurrence

11. The risks for recurrence of squamous intraepithelial lesions and cervical cancer after conventional therapy are increased among HIV-infected women. The prevention of illness associated with recurrence depends on careful follow-up of patients after treatment. Patients should be monitored with frequent cytologic screening and, when indicated, with colposcopic examination for recurrent lesions (AI) (133,143).

12. In one recent study of HIV-infected women treated for HSILs using standard therapy, low-dose intravaginal 5-fluorouracil (2 grams twice a week for 6 months) reduced the short-term risk for recurrence and possibly the grade of recurrence (135). However, clinical experience with this therapy is too limited to provide a recommendation for routine use.

Special Considerations

Pregnant Women

13. Use of intravaginal 5-fluorouracil to prevent recurrent dysplasia is not recommended during pregnancy.

Hepatitis C Virus Infection

Prevention of Exposure

1. The chief route of hepatitis C virus (HCV) transmission in the United States is injection drug use. Because injection drug use is a complex behavior, clinicians should assess the individual's readiness to change this practice and encourage efforts to provide patient education and support directed at recovery.

Patients who inject drugs should be advised (136-138) --

- to stop using injection drugs (AIII);
 - to enter and complete a substance-abuse treatment program, including a relapse prevention program (AIII).
- If they are continuing to inject drugs (BIII) -***
- to never reuse or share syringes, needles, rinse water, or drug preparation equipment; if, nonetheless, injection equipment that has been used by other persons is shared, to first clean the equipment with bleach and water as is recommended for prevention of HIV;
 - to use only sterile syringes obtained from a reliable source (e.g., pharmacies or syringe exchange programs);
 - to use sterile (e.g., boiled) water to prepare drugs; if not possible, to use clean water from a reliable source (e.g., fresh tap water);
 - to use a new or disinfected container ("cooker") and a new filter ("cotton") to prepare drugs;
 - to clean the injection site with a new alcohol swab before injection; and
 - to safely dispose of syringes after one use.

2. Persons considering tattooing or body piercing should be informed of potential risks of acquiring bloodborne infections, which could be transmitted if equipment is not sterile or if proper infection control procedures are not followed (e.g., washing hands, using latex gloves, and cleaning and disinfecting surfaces) (138) (BIII).

3. To reduce risks for acquiring bloodborne infections, patients should be advised not to share dental appliances, razors, or other personal care articles (BIII).
4. Although the efficiency of sexual transmission of HCV is low, safe-sexual practices should be encouraged for all HIV infected persons, and barrier precautions (e.g., latex condoms) are recommended to reduce the risk for exposure to sexually transmitted pathogens (AII).

Prevention of Disease

5. All patients **with HIV infection** should be screened for HCV infection (BIII). **Screening is recommended because some HIV-infected patients (e.g., injection drug users, and patients with hemophilia) are at increased risk for HCV infection and HCV related disease, and because knowledge of HCV status is important for management of all HIV-infected patients (e.g., to interpret and manage elevated liver related tests). Screening should be performed** by using enzyme immunoassays (EIAs) licensed for detection of antibody to HCV (anti-HCV) in blood (BIII). Positive anti-HCV results should be verified with additional testing (i.e., recombinant immunoblot assay [RIBA™] or reverse transcriptase polymerase chain reaction for HCV RNA). The presence of HCV RNA in blood might also be assessed in HIV-infected persons with undetectable antibody but other evidence of chronic liver disease (e.g., unexplained elevated liver-specific enzymes) or when acute HCV infection is suspected (CIII).
6. Persons coinfecting with HIV and HCV should be advised not to drink excessive amounts of alcohol (AII). Avoiding alcohol altogether might be prudent because it is unclear whether even occasional alcohol use (e.g., less than 12 ounces of beer or less than 10 grams of alcohol per day) increases the incidence of cirrhosis among HCV-infected persons (CIII).
7. Patients with chronic hepatitis C should be vaccinated against hepatitis A because a) the risk for fulminant hepatitis associated with hepatitis A appears increased in such patients; b) hepatitis A vaccine is safe for HIV-infected persons; and c) although immunogenicity is reduced in patients with advanced HIV infection, more than two thirds of patients develop protective antibody responses (BIII). Prevacination screening for total (IgG and IgM) antibody to hepatitis A virus is cost-effective and therefore recommended when greater than 30% prevalence of hepatitis A virus antibody is expected in the population being screened (e.g., persons greater than 40 years of age) (139). **Patients should also be immunized for HBV if they are susceptible** (BIII).
8. HIV-HCV-coinfecting patients **may develop HCV associated liver disease over a shorter time course than patients infected with HCV alone (140-143)** and should be evaluated for chronic liver disease and for the possible need for treatment. **Limited data suggest that HCV treatment can be safely provided to patients coinfecting with HIV and HCV.** Because the optimal means of treating coinfecting patients has not been established and many HIV-infected patients have conditions that complicate therapy (e.g., depression), this care should occur in a clinical trial or be coordinated by providers with experience treating both HIV and HCV infections (BIII).
9. In some studies, the incidence of antiretroviral-associated liver enzyme elevations has been increased in patients coinfecting with HIV and HCV (141); such increases might not require treatment modifications. Thus, although liver enzymes should be carefully monitored, HAART should not be routinely withheld from patients coinfecting with HIV and HCV (DIII). However, coinfecting patients initiating HAART might have an inflammatory reaction that mimics an exacerbation of underlying liver disease. In this situation, careful monitoring of liver function is required.

Prevention of Recurrence

10. If the serum HCV RNA level becomes undetectable during HCV therapy and remains undetectable for 6 months after HCV therapy is stopped (sustained virologic response), greater than 90% of HIV-uninfected patients with hepatitis C will remain HCV RNA negative for greater than 5 years and have improved liver histology (144). For HIV-HCV-coinfecting patients, the durability of treatment response and requirement for maintenance therapy are unknown.

Special Considerations

Children

11. **Transmission of HCV from mother to child appears to be more frequent for mothers co-infected with HIV and HCV than for those infected with HCV alone. Therefore, children born to women coinfecting with HIV and HCV should be tested for HCV infection (136) (BI).** Because maternal HCV antibody can persist for up to 18 months, testing should be performed at or after 2 years of age. If earlier diagnosis is desired, RT-PCR for HCV RNA may be performed after 1 month of age and should be repeated at a subsequent time. The average rate of HCV infection among infants born to coinfecting women is approximately 15% (range, 5-36%) (145). Data are limited on the natural history of HCV infection and treatment of chronic hepatitis C in children.

References

1. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. *MMWR* 1995;44(No. RR-8).
2. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. *Clin Infect Dis* 1995;21(suppl 1):S32-S43.
3. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. *Ann Intern Med* 1996;124:348-68.
4. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *MMWR* 1997;46(No. RR-12).
5. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *MMWR* 1999;48(No. RR-10).
6. USPHS/IDSA prevention of opportunistic infections working group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. *Clin Infect Dis* 1997;25(suppl 3):S313-S315.
7. USPHS/IDSA prevention of opportunistic infections working group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *Clin Infect Dis* 30 (Suppl 1): S1-S93, 1999.
8. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *Ann Intern Med* 1997;127:922-46.
9. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *Am Fam Physician* 1997;56:823-30, 1131-46, 1387-92.
10. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *Am Fam Physician* 2000;61(1):163-171.
11. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *Pediatrics* 1998;102:1064-85.
12. Kaplan JE, Masur H, Jaffe HW, Holmes KK. Reducing the impact of opportunistic infections in patients with HIV infection: new guidelines. [Editorial]. *JAMA* 1995;274(4):347-348.
13. Kaplan JE, Masur H, Jaffe HW, Holmes KK. Preventing opportunistic infections in persons infected with HIV: 1997 guidelines [Editorial]. *JAMA* 1997;278:337-8.
14. CDC. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and guidelines for use of antiretroviral agents in HIV-infected adults and adolescents. *MMWR* 1998;47 (No. RR-5).
15. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW, and the Adult/Adolescent Spectrum of Disease Group. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. *AIDS* 1999;13:1687-95.
16. USPHS/IDSA Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. <http://www.hivatis.org>.
17. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. *Clin Infect Dis* 1994;18:421.
18. Phair J, Munoz A, Saah A, Detels R, et al, and the Multicenter AIDS Cohort Study Group. The risk of *Pneumocystis carinii* pneumonia among men infected with HIV-1. *N. N Engl J Med* 1990;322: 61-5.
19. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. *J Infect Dis* 1998;178:1126-32.
20. CDC. Guidelines for prophylaxis against *Pneumocystis carinii* pneumonia for persons infected with human immunodeficiency virus. *MMWR* 1989;38(suppl 5):1-9.
21. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1995;332:693-9.
22. Schneider MME, Hoepelman AIM, Schattenkerk JKME, et al., and the Dutch AIDS Treatment Group. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis

- against *Pneumocystis carinii* pneumonia in patients with human immunodeficiency virus infection. *N Engl J Med* 1992;327:1836-41.
23. Schneider MME, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against *Pneumocystis carinii* pneumonia in patients with human immunodeficiency virus. *J Infect Dis* 1995;171:1632-6.
 24. El-Sadr W, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice weekly trimethoprim-sulfamethoxazole for the prevention of *Pneumocystis carinii* pneumonia in HIV infected individuals. *Clin Infect Dis* 1999;29:775-83.
 25. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. *Ann Intern Med* 1992;117:106-11.
 26. Hardy WD, Feinberg J, Finkelstein DM, et al., for the AIDS Clinical Trials Group. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. *N Engl J Med* 1992;327:1842-8.
 27. Leoung G, Standford J, Giordano M, et al. A randomized, double-blind trial of TMP/SMX dose escalation vs. direct challenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever [Abstract]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997. Abstract no. LB10.
 28. Para MF, Dohn M, Frame P, Becker S, Finkelstein D, Walawander A, for the ACTG 268 Study Team. reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for *Pneumocystis carinii* pneumonia: AIDS Clinical Trials Group 268 *J Acquir Immune Defic Syndr* 2000;24:337-43.
 29. Podzameczer D, Salazar A, Jiminez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of *Pneumocystis* pneumonia and toxoplasmosis in patients infected with HIV. *Ann Intern Med* 1995;122:755-61.
 30. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for *Pneumocystis carinii* pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. *Clin Infect Dis* 1995;20:531-41.
 31. Chan C, Montaner J, LeFebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of *Pneumocystis carinii* pneumonia in human immunodeficiency virus infected subsets intolerant of trimethoprim or sulfamethoxazole. *J Infect Dis* 1999;180:369-376.
 32. El-Sadr W, Murphy RL, Yurik RM, et al. Atovaquone compared with dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. *N Engl J Med* 1998;339:1889-95.
 33. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against *Pneumocystis carinii* pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. *N Engl J Med* 1999;340:1301-6.
 34. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of *Pneumocystis carinii* pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. *Lancet* 1999;353:1293-8.
 35. Yangco BF, VonBargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis for *pneumocystis carinii* pneumonia in patients with HIV infection. *Ann Intern Med* 2000;132:201-205.
 36. Schneider MME, Borleffs JCC, Stolk RP, Jaspers CAJJ, Hoepelman AIM. Discontinuation of *Pneumocystis carinii* pneumonia prophylaxis in HIV-1 infected patients treated with highly active antiretroviral therapy. *Lancet* 1999;353:201-3.
 37. Dworkin M, Hanson D, Jones J, Kaplan J, and the Adult/Adolescent Spectrum of HIV Disease Project (ASD). Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T-lymphocyte counts above prophylaxis thresholds. *J Infect Dis* 2000;182:611-5.
 38. Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B. discontinuation of primary prophylaxis for *Pneumocystis carinii* pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. *J Infect Dis* 2000;181:1635-42.
 39. Lopez JC, Miro JM, Pena JM, Podzameczer D, and the GESIDA 04/98 Study Group. A randomized trial of the discontinuation of primary and secondary prophylaxis against *Pneumocystis carinii* pneumonia after HAART in patients with hiv infection. *N Engl J Med* 2001;344(3):159-167.
 40. Furrer H, Opravil M, Rossi M et al. Discontinuation of primary prophylaxis in HIV infected patients at high risk of pneumocystis pneumonia: a prospective multicentre study. *AIDS* 2001;15:501-507.

41. Kirk O, Lundgren JD, Pederson C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? *AIDS* 1999;13:1647-51.
42. Soriano V, Dona C, Rodriguez-Rosado, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. *AIDS* 2000, 14:383-386.
43. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, dArminio Monforte A, Schneider M, Lundgren, J. Discontinuation of secondary prophylaxis against *Pneumocystis carinii* pneumonia in patients with HIV infection who have a response to antiretroviral therapy. *NEJM* 2001;344:168-174.
44. CDC. 1995 revised guidelines for prophylaxis against *Pneumocystis carinii* pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. *MMWR* 1995 44(No. RR-4).
45. Department of Agriculture: <http://www.foodsafety.gov>.
46. Miro JM, Podzamczer D, Pena JM, Alberdi J, et al. Discontinuation of Primary and Secondary *Toxoplasma gondii* Prophylaxis is Safe in HIV-1 Infected Patients after Immunological Recovery with HAART. Final Results of the GESIDA 04/98 Study [Abstract]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society for Microbiology, 2000. Abstract No. L16
47. Furrer H, Oparavil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1 infected patients at high risk of toxoplasma encephalitis. *Lancet* 2000;355:2217-8.
48. Katlama C, DeWit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. *Clin Infect Dis* 1996;22:268-75.
49. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. *Ann Intern Med* 1992;116:33-43.
50. Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. *JAMA* 1998;279:384-6.
51. Fichtenbaum CJ, Zackin R, Feinberg J, et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. *AIDS* 2000;14:2889-93.
52. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000;49 (No RR-6).
53. CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. *MMWR* 1998;47;(RR-20).
54. Centers for Disease Control and Prevention. Notice to Readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. *MMWR* 2000; 49:183-9.
55. Masur H, and the Public Health Service Task Force on Prophylaxis and Therapy for *Mycobacterium avium* complex. Recommendations on prophylaxis and therapy for disseminated *Mycobacterium avium* complex disease in patients infected with the human immunodeficiency virus. *N Engl J Med* 1993;329:898-904.
56. Benson CA, Williams PL, Cohn DL, and the ACTG 196/CPCRA 009 Study Team. Clarithromycin or Rifabutin alone or in combination for primary prophylaxis of *Mycobacterium avium* complex disease in patients with AIDS: a randomized, double-blinded, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. *J Infect Dis* 2000;181(4):1289-97.
57. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated *Mycobacterium avium* complex infection in patients with advanced acquired immunodeficiency syndrome. *N Engl J Med* 1996;335:384-91.
58. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated *Mycobacterium avium* complex with weekly azithromycin, daily rifabutin, or both. *N Engl J Med* 1996;335:392-8.
59. El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, Zeh D, Gallagher B, Mannheimer SB, Martinez A, Gordin F. discontinuation of prophylaxis for mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. *NEJM* 2000;342:1085-92.
60. Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA. Discontinuation of mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trial Group 362 Study Team. *Ann Intern Med* 2000;133:493-503.

61. Furrer H, Rossi M, Telenti A, Lederberger B. Discontinuing or withholding primary prophylaxis against *Mycobacterium avium* in patients on successful antiretroviral combination therapy. *AIDS* 2000;14:1409-1412.
62. Gordin F, Sullam P, Shafran S, Cohn DL, Wynne B, Paxton L, Perry K, Horsburgh CR. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with *Mycobacterium avium* complex (MAC). *Clin Infect Dis* 1999;28(5):1080-5.
63. Benson C, Williams P, Currier J, et al. ACTG223: An open, prospective, randomized study comparing efficacy and safety of clarithromycin (C) plus ethambutol (E), rifabutin (R), or both for treatment (Rx) of MAC disease in patients with AIDS [Abstract]. In: Program and abstracts: 6th Conference on Retroviruses and Opportunistic Infections. Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1999. Abstract no. 249.
64. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic *Mycobacterium avium* complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. *Ann Intern Med* 1994;121:905-11.
65. Cohn DL, Fisher E, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated *Mycobacterium avium* complex disease in AIDS patients: excess mortality associated with high dose clarithromycin. *Clin Infect Dis* 1999;29(1):125-33.
66. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic *Mycobacterium avium* complex disease in patients with HIV infection. *AIDS* 1997;11:311-7.
67. Rabaud C, Jouan M, Mary-Krausse M, et al. *Mycobacterium avium* (MAC) infections during HAART era (1996-98) in HIV-infected French patients [Abstr. 2054]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000; San Francisco, CA.
68. Aberg JA, Yijko DM, Jacobson MA. Eradication of AIDS-related disseminated *Mycobacterium avium* complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. *J Infect Dis* 1998;178:1446-9.
69. Shafran SD, Gill MJ, Lajonde RG, et al. Successful Discontinuation of MAC Therapy Following Effective HAART [Abstr. 547]. In Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001; Chicago, IL.
70. Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. *Obstet Gynecol* 1998;91:165-8.
71. Medical Economics Company, Inc. Physicians' desk reference. 55th edition. Montvale, New Jersey: Medical Economics Company, Inc., 2001.
72. Dworkin MS, Ward JW, Hanson DL, et al. Pneumococcal disease among HIV-Infected persons: incidence, risk factors, and impact of vaccination. *Clin Infect Dis* 2001;32(5):794-800.
73. Guerrero M, et al. Pneumonia in HIV-Infected Patients: A case-control survey of factors involved in risk and prevention. *AIDS* 1999;13:1975-1981.
74. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. *J Infect Dis* 1996;173:857-62.
75. CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 1997;46(No. RR-8).
76. Breiman RF, Keller DW, Phelan MA. Evaluation of effectiveness of 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. *Arch Intern Med* 2000;160:2633-2638.
77. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised, and placebo-controlled trial. *Lancet* 2000;355:2106-2111.
78. Centers for Disease Control and Prevention. Recommended childhood immunization schedule - United States. *MMWR* 2001;50:7-11.
79. American Academy of Pediatrics. Committee on Infectious Diseases. Policy Statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. *Pediatrics* 2000;106(2 Pt 1):362-366.
80. CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2000;49(RR9):1-35.
81. Spector SA, Gerber RD, McGrath N et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. *N Engl J Med* 1994;331:1181-1187.
82. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with

- clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1995;332:700-5.
83. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1997;126:689-96.
 84. Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. *Clin Infect Dis* 1998;27:1369-75.
 85. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. *Clin Infect Dis* 1996;22:336-40.
 86. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. *Am J Med Genet* 1997;72:253-6.
 87. Janssen Pharmaceutical Company. Product information: Sporanox (itraconazole) oral solution. In: Medical Economics Company, Inc. Physicians' desk reference. 53rd edition. Montvale, New Jersey: Medical Economics Company, Inc., 1999;1441.
 88. Bozzette SA, Larsen R, Chiu J, et al. A controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. *N Engl J Med* 1991;324:580.
 89. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1992;326:793.
 90. Saag MS, and the NIAID Mycoses Study Group. Comparison of fluconazole versus itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis. *Clin Infect Dis* 1999; 28(2):291-6.
 91. Aberg JA, Price RW, Heeren DM, et al. Discontinuation of antifungal therapy for cryptococcosis after immunologic response to antiretroviral therapy [Abstr. 250]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000; San Francisco, CA.
 92. Mussini C, Cossarizza A, Pezzotti P, et al. Discontinuation or continuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with HAART [Abstr. 546]. In: Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001; Chicago, IL.
 93. McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. *Clin Infect Dis* 1999;28:1049-56.
 94. Wheat J, Hafner R, Wulfsohn M, et al., and the NIASID Clinical Trials and Mycoses Study Group Collaborators. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. *Ann Intern Med* 1993;118:610-6.
 95. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. *Ann Intern Med* 2000;133(9):676-686.
 96. Spector SA, McKinley GF, Lalezari JFP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. *N Engl J Med* 1996;334:1491-7.
 97. Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. *AIDS* 1998;12:269-77.
 98. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. *J Infect Dis* 1998;177:48-56.
 99. Martin DF, Kupperman BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. *N Engl J Med* 1999;340:1063-70.
 100. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. *N Engl J Med* 1995;333:615-20.
 101. Studies of Ocular Complications of AIDS Research Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial. A randomized, controlled trial. *Ann Intern Med* 1997;126:264-74.
 102. Palestine AG, Polis MA, DeSmet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. *Ann Intern Med* 1991;115:665-73.
 103. Spector SA, Weingeist T, Pollard RE, et al. A randomized, controlled study of intravenous

- ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. *J Infect Dis* 1993;168:557-63.
104. Studies of Ocular Complications of AIDS in collaboration with the AIDS Clinical Trials Group: Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. *Arch Ophthalmol* 1996;114:23-33.
 105. Diaz-Llopis M, España E, Muñoz G, et. al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. *Brit J Ophthalmol* 1994;78:120-124.
 106. Lewis RA, Carr LM, Doyle K, et al. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. *Ann Intern Med* 1997;126:264.
 107. DeSmet MD, Meenken C, van den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. *Ocular Immunol Inflamm* 1999;7:189-98.
 108. Kirsch LS, Arevelo JF, Chavez de la Paz E, et. al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with AIDS. *Ophthalmology* 1995; 102:533-543.
 109. Young S, Morlet N, Besen G, et.al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. *Ophthalmology* 1998;105:1404-1410.
 110. Tural C, Romeu J, Sicrera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. *J Infect Dis* 1998;177:1080-3.
 111. Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. *Ophthalmology* 1998; 105:1259-64.
 112. MacDonald JC, Torriani FJ, Morse, et. al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. *J Infect Dis* 1998;177:1182-7.
 113. Whitcup SM, Fortin E, Lindblad AS, et. al. Discontinuation of anti-cytomegalovirus therapy in persons with HIV infection and cytomegalovirus retinitis. *JAMA* 1999;282:1633-1637.
 114. Jabs DA, Bolton SG, Dunn JP, et. al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. *Am J Ophthalmol* 1998;126:817-22.
 115. Jouan M, Saves H, Tubiana R et al. Discontinuation of maintenancetherapy for cytomegalovirus retinitis in HIV infected patients receving highly active antiretroviral therapy. Restimop Study Team. *AIDS* 2001;15:23-31.
 116. Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. *J Clin Invest* 101:497-502.
 117. Salmon-Cerm D, Mazon M-C, Caput S, et al. Plasma cytomegalovirus DNA, PP65 antigenaemia and a low CD4 cell count remain reisk factors for cytomegalovirus diseasein patients receiving highly active antiretroviral therapy. *AIDS* 2000;14:1042-1049.
 118. Torriani FJ, Freeman WR, MacDonald JC, et. al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. *AIDS* 2000;14:173-80.
 119. Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infectedmen. *J Infect Dis* 1998; 178:1616-22.
 120. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. *Ann Intern Med* 1998;128:21-8.
 121. CDC. Pregnancy outcomes following systemic prenatal acyclovir exposure: June 1, 1984-June 30, 1993. *MMWR* 1993;42:806-9.
 122. Jacobson LP, Jenkins FJ, Springer G, et al. Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. *J Infect Dis* 2000;181:1940-9.
 123. Renwick N, Halaby T, Weverling GJ, et al. Seroconversion ofr human heresvirus 8 during HIV infecitonis highly predictive of Kaposi's sarcoma. *AIDS* 1998;12:2481-8.
 124. Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. *N Engl J Med* 1998;338:948-54.
 125. Pauk J, Huang ML, Brodie SJ, et. al. Mucosal shedding of human herpesvirus 8. *N Engl J Med* 2000;343:1369-77.
 126. Cannon MJ, Dollard SC, Smith DK, et al; HIV Epidemiology Research Study Group. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. *N Engl J Med* 2001;344:637-643.
 127. Whitley D, Smith NA, Mathew S et al. Human herpesvirus 8 seroepidemiology among women and detection in the genital tract of seropositive women. *J Infect Dis* 1999;179:254-6.
 128. Ledergerber B, Egger M, Erard V,et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. *JAMA* 1999;23:2220-6.

129. Bourbouli D, Whitby D, Boshoff C, et al. Serologic evidence of mother to child transmission of Kaposi-sarcoma-associated herpesvirus infection. *JAMA* 1998;280:31-2.
130. He J, Bhat G, Kankasa C, et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS. *J Infect Dis* 1998;178:787-90.
131. Sitas F, Newton R, Boshoff C. Increasing probability of mother to child transmission of HHV-8 with increasing maternal antibody titer for HHV-8. *N Engl J Med* 1999;340:1923.
132. Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. *Lancet* 2000;356:1062-65.
133. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. *JAMA* 1994;271:1866-9.
134. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. *JAMA* 1999;281:1822-9.
135. Maiman M, Watts DH, Andersen J, et al. Vaginal 5-fluorouracil for high grade cervical dysplasia in HIV-infection: A randomized trial. *Obstet Gynecol* 1999;94(6):954-61.
136. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR* 1998;47 (No. RR-19).
137. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis B and C virus infection. *JAMA* 2000;283:74-80.
138. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. *Lancet* 1997;350:1425-31.
139. Eyster ME, Dimondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. *J Acquir Immune Defic Syndr* 1993;6:602-10.
140. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. *Lancet* 1997;350:1425-31.
141. Thomas DL, Shih JW, Alter HG et al. Effect of HIV infection on hepatitis C virus infection among injection drug users. *J Infect Dis* 1996;174:690-5.
142. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy [Letter]. *AIDS* 1998;12:1256.
143. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or Hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease containing antiretroviral regimen in human immunodeficiency virus infected patients. The APROCO Study Group. *Antimicrob Agents Chemother.* 2000;44:3451-5.
144. Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon in chronic hepatitis C. *Ann Intern Med* 1996;124:1058-60.
145. Mast EE, Alter MJ. Hepatitis C. *Semin Pediatr Infect Dis* 1997;8:17-22.

TABLE 1. Prophylaxis to Prevent First Episode of Opportunistic Disease in Adults and Adolescents Infected with Human Immunodeficiency Virus

Pathogen	Indication	Preventive Regimens	
		First Choice	Alternatives
I. Strongly recommended as standard of care <i>Pneumocystis carinii</i> ¹	CD4+ count <200/ μ L or oropharyngeal candidiasis	Trimethoprim-sulfamethoxazole (TMP-SMZ), 1 DS po q.d. (AI) TMP-SMZ, 1 SS po q.d. (AI)	Dapsone, 50 mg po b.i.d. or 100 mg po q.d. (BI); dapsone, 50 mg po q.d. plus pyrimethamine, 50 mg po q.w. plus leucovorin 25 mg po q.w. (BI); dapsone 200 mg po plus pyrimethamine, 75 mg po plus leucovorin, 25 mg po q.w. (BI); aerosolized pentamidine, 300 mg q.month via Respigard II ^(TM) nebulizer (BI); atovaquone, 1500 mg po q.d. (BI); TMP-SMZ, 1 DS po t.i.w. (BI)
<i>Mycobacterium tuberculosis</i> Isoniazid-sensitive ²	TST reaction ≥ 5 mm or prior positive TST result without treatment or contact with case of active tuberculosis regardless of TST result (BIII)	Isoniazid, 300 mg po plus pyridoxine, 50 mg po q.d. x 9 mo (AII) or isoniazid, 900 mg po plus pyridoxine, 100 mg po b.i.w. x 9 mo (BII)	Rifampin, 600 mg po q.d. (BIII) x 4 mo or rifabutin 300 mg po q.d. (CIII) x 4 mo Pyrazinamide, 15-20 mg/kg po q.d. x 2 mo plus either rifampin, 600 mg po q.d. (BI) x 2 mo or rifabutin, 300 mg po q.d. (CIII) x 2 mo
Isoniazid-resistant	Same as above; high probability of exposure to isoniazid-resistant tuberculosis	Rifampin 600 mg po (AIII) or rifabutin, 300 mg po (BIII) q.d. x 4 mo	Pyrazinamide 15-20 mg/kg po q.d. plus either rifampin, 600 mg po (BI) or rifabutin, 300 mg po (CIII) q.d. x 2 mo
Multidrug-(isoniazid and rifampin) resistant	Same as above; high probability of exposure to multidrug-resistant tuberculosis	Choice of drugs requires consultation with public health authorities. Depends on susceptibility of isolate from source patient	-----

TABLE 1. Prophylaxis to Prevent First Episode of Opportunistic Disease in Adults and Adolescents Infected with Human Immunodeficiency Virus (continued)

Pathogen	Indication	Preventive Regimens	
		First Choice	Alternatives
<i>Toxoplasma gondii</i> ³	IgG antibody to <i>Toxoplasma</i> and CD4+ count <100/ μ L	TMP-SMZ, 1 DS po q.d. (AII)	TMP-SMZ, 1 SS po q.d. (BIII); dapsone, 50 mg po q.d. <i>plus</i> pyrimethamine, 50 mg po q.w. <i>plus</i> leucovorin, 25 mg po q.w. (BI); dapsone, 200 mg po plus pyrimethamine[^], 75 mg po plus leucovorin, 25 mg po q w (BI) ; atovaquone, 1500 mg po q.d. with or without pyrimethamine, 25 mg po q.d. <i>plus</i> leucovorin, 10 mg po q.d. (CIII)
<i>Mycobacterium avium</i> complex ⁴	CD4+ count <50/ μ L	Azithromycin, 1,200 mg po q.w., (AI) or clarithromycin, ⁴ 500 mg po b.i.d. (AI)	Rifabutin, 300 mg po q.d. (BI); azithromycin, 1,200 mg po q.w. <i>plus</i> rifabutin, 300 mg po q.d. (CI)
Varicella zoster virus (VZV)	Significant exposure to chickenpox or shingles for patients who have no history of either condition or, if available, negative antibody to VZV	Varicella zoster immune globulin (VZIG), 5 vials (1.25 mL each) im, administered 96 h after exposure, ideally within 48 h (AIII)	
II. Generally Recommended			
<i>Streptococcus pneumoniae</i> ⁵	CD4+ count \geq 200/ μ L	23 valent polysaccharide vaccine, 0.5 mL im [BII]	None
Hepatitis B virus ^{6,7}	All susceptible (anti-HBc-negative) patients	Hepatitis B vaccine: 3 doses (BII)	None

TABLE 1. Prophylaxis to Prevent First Episode of Opportunistic Disease in Adults and Adolescents Infected with Human Immunodeficiency Virus - continued

Pathogen	Indication	Preventive Regimens	
		First Choice	Alternatives
Influenza virus ^{6,8}	All patients (annually, before influenza season)	Inactivated trivalent influenza virus vaccine: one annual dose (0.5 mL) im (BIII)	Oseltamivir, 75 mg po q.d. (influenza A or B) (CIII); rimantadine, 100 mg po b.i.d. (CIII), or amantadine, 100 mg po b.i.d. (CIII) (influenza A only)
Hepatitis A virus ^{6,7}	All susceptible (anti-HAV-negative) patients at increased risk for HAV infection (e.g., illicit drug users, men who have sex with men, hemophiliacs) or with chronic liver disease, including chronic hepatitis B or hepatitis C	Hepatitis A vaccine: two doses (BIII)	None
III. Evidence for Efficacy but Not Routinely Indicated			
Bacteria	Neutropenia	Granulocyte-colony-stimulating factor (G-CSF), 5-10 µg/kg sc q.d. x 2-4 w or granulocyte-macrophage colony-stimulating factor (GM-CSF), 250 µg/m ² sc iv x 2-4 w (CII)	None
<i>Cryptococcus neoformans</i>	CD4+ count <50/µL	Fluconazole, 100-200 mg po q.d. (CI)	Itraconazole capsule , 200 mg po q.d. (CIII)
<i>Histoplasma Capsulatum</i> ⁹	CD4+ count <100/µL, endemic geographic area	Itraconazole capsule, 200 mg po q.d.(CI)	None
Cytomegalovirus (CMV) ¹⁰	CD4+ count <50/µL and CMV antibody positivity	Oral ganciclovir, 1g po t.i.d. (CI)	None

NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval. The Respigard IITM nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendation and the quality of evidence supporting it (see page 7).

ABBREVIATIONS: Anti-HBc = antibody to hepatitis B core antigen; b.i.w.= twice a week; DS = double-strength tablet; HAART = highly active antiretroviral therapy; HAV = hepatitis A virus; HIV = human immunodeficiency virus; im = intramuscular; iv = intravenous; po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly; SS= single-strength tablet; t.i.w. = three times a week; TMP-SMZ = trimethoprim-sulfamethoxazole; sc = subcutaneous; and TST = tuberculin skin test.

¹Prophylaxis should also be considered for persons with a CD4+ percentage of <14%, for persons with a history of an AIDS-defining illness, and possibly for those with CD4+ counts >200 but <250 cells/µL. TMP-SMZ also reduces the frequency of toxoplasmosis and some bacterial infections. Patients receiving dapson should be tested for glucose-6 phosphate dehydrogenase deficiency. A dosage of 50 mg q.d. is probably less effective than

100 mg q.d. The efficacy of parenteral pentamidine (e.g., 4 mg/kg/month) is uncertain. Fansidar (sulfadoxine-pyrimethamine) is rarely used because of severe hypersensitivity reactions. Patients who are being administered therapy for toxoplasmosis with sulfadiazine-pyrimethamine are protected against *Pneumocystis carinii* pneumonia and do not need additional prophylaxis against PCP.

²Directly observed therapy is recommended for isoniazid, e.g., 900 mg b.i.w.; isoniazid regimens should include pyridoxine to prevent peripheral neuropathy. **If rifampin or rifabutin are administered concurrently with protease inhibitors or non-nucleoside reverse transcriptase inhibitors, careful consideration should be given to potential pharmacokinetic interactions (54). See discussion of rifampin interactions in paragraph 11 in section on Tuberculosis. There have been reports of fatal and severe liver injury associated with the treatment of latent TB infection in HIV-uninfected persons treated with the 2 month regimen of daily rifampin and pyrazinamide; therefore it may be prudent to use regimens that do not contain pyrazinamide in HIV-infected persons whose completion of treatment can be assured (CDC. Update: Fatal and Severe Liver Injuries Associated with Rifampin and Pyrazinamide for Latent Tuberculosis Infection and Revisions in American Thoracic Society/CDC Recommendations, United States 2001 MMWR 50 (No. 34), Aug 31, 2001).** Exposure to multidrug-resistant tuberculosis might require prophylaxis with two drugs; consult public health authorities. Possible regimens include pyrazinamide plus either ethambutol or a fluoroquinolone.

³Protection against toxoplasmosis is provided by TMP-SMZ, dapsone plus pyrimethamine, and possibly by atovaquone. Atovaquone may be used with or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection.

⁴See paragraph 9, in section on “Disseminated Infection with *Mycobacterium avium* complex” and references 53-54 for discussion of drug interactions.

***During pregnancy, azithromycin is preferred over clarithromycin because of the teratogenicity in animals of clarithromycin.**

⁵Vaccination may be offered to persons who have a CD4+ T-lymphocyte count <200 cells/μL, although the efficacy is likely to be diminished. Revaccination 5 years after the first dose or sooner if the initial immunization was given when the CD4+ count was <200 cells/μL and the CD4+ count has increased to >200 cells/μL on HAART is considered optional. Some authorities are concerned that immunizations might stimulate the replication of HIV.

⁶**Although data demonstrating clinical benefit of these vaccines in HIV-infected persons are not available, it is logical to assume that those patients who develop antibody responses will derive some protection. Some authorities are concerned that immunizations might stimulate HIV replication, although for influenza vaccination, a large observational study of HIV-infected persons in clinical care showed no adverse effect of this vaccine, including multiple doses, on patient survival (J. Ward, CDC, personal communication). Also, this concern may be less relevant in the setting of HAART. However, because of the theoretical concern that increases in HIV plasma RNA following vaccination during pregnancy might increase the risk of perinatal transmission of HIV, providers may wish to defer vaccination for such patients until after HAART is initiated.**

⁷Hepatitis B vaccine has been recommended for all children and adolescents and for all adults with risk factors for hepatitis B virus (HBV). For persons requiring vaccination against both hepatitis A and hepatitis B, a combination vaccine is now available. For additional information regarding vaccination against hepatitis A and B, see CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991;40 (No RR13).

⁸Oseltamivir is appropriate during outbreaks of either influenza A or influenza B. Rimantadine or amantadine are appropriate during outbreaks of influenza A (although neither rimantadine nor amantadine is recommended during pregnancy). Dosage reduction for antiviral chemoprophylaxis against influenza might be indicated for decreased renal or hepatic function, and for persons with seizure disorders. Physicians should consult the drug package inserts and the annual CDC influenza guidelines for more specific information about adverse effects and dosage adjustments. For additional information about vaccination, antiviral chemoprophylaxis and therapy against influenza, see: CDC. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2001;50(No. RR-4).

⁹In a few unusual occupational or other circumstances, prophylaxis should be considered; consult a specialist.

¹⁰Acyclovir is not protective against CMV. Valacyclovir is not recommended because of an unexplained trend toward increased mortality observed in persons with AIDS who were being administered this drug for prevention of CMV disease.

TABLE 2. Prophylaxis to Prevent Recurrence of Opportunistic Disease in Adults (after chemotherapy for acute disease) in Adults and Adolescents Infected with Human Immunodeficiency Virus

Pathogen	Indication	Preventive Regimens	
		First Choice	Alternatives
Recommended as standard of care			
<i>Pneumocystis carinii</i>	Prior <i>P. carinii</i> pneumonia	Trimethoprim-sulfamethoxazole (TMP-SMZ), 1 DS po q.d. (AI); TMP-SMZ 1 SS po q.d. (AI)	Dapsone, 50 mg po b.i.d. or 100 mg po q.d. (BI); dapsone, 50 mg po q.d. <i>plus</i> pyrimethamine, 50 mg po q.w. <i>plus</i> leucovorin, 25 mg po q.w. (BI); dapsone, 200 mg po <i>plus</i> pyrimethamine, 75 mg po <i>plus</i> leucovorin, 25 mg po q.w. (BI); aerosolized pentamidine, 300 mg q.m. via Respirgard II TM nebulizer (BI); atovaquone, 1500 mg po q.d. (BI); TMP-SMZ, 1 DS po t.i.w. (CI)
<i>Toxoplasma gondii</i> ¹	Prior toxoplasmic encephalitis	Sulfadiazine, 500-1,000 mg po q.i.d. <i>plus</i> pyrimethamine, 25-50 mg po q.d. <i>plus</i> leucovorin, 10-25 mg po q.d. (AI)	Clindamycin, 300-450 mg po q 6-8 h <i>plus</i> pyrimethamine, 25-50 mg po q.d. <i>plus</i> , leucovorin 10-25 mg po q.d. (BI); atovaquone 750 mg po q 6-12 h with or without pyrimethamine, 25 mg po q.d. <i>plus</i> leucovorin, 10 mg po, q.d. (CIII)
<i>Mycobacterium avium</i> complex ²	Documented disseminated disease	Clarithromycin, ² 500 mg po b.i.d. (AI) <i>plus</i> ethambutol, 15 mg/kg po q.d. (AII); with or without rifabutin, 300 mg po q.d. (CI)	Azithromycin, 500 mg po q.d. (AII) <i>plus</i> ethambutol, 15 mg/kg po q.d.(AII); with or without rifabutin, 300 mg po q.d. (CI)
<i>Cytomegalovirus</i>	Prior end-organ disease	Ganciclovir, 5-6 mg/kg/day iv 5-7 days/wk or 1,000 mg po t.i.d. (AI); or foscarnet, 90-120 mg/kg iv q.d. (AI); or (for retinitis) ganciclovir sustained-release implant q 6-9 months <i>plus</i> ganciclovir, 1.0-1.5 g po t.i.d. (AI);	Cidofovir, 5 mg/kg iv q.o.w. with probenecid 2 grams po 3 hours before the dose followed by 1 gram po 2 hours after the dose, and 1 gram po 8 hours after the dose (total of 4 grams) (AI). Fomivirsen 1 vial (330 µg) injected into the vitreous, then repeated every 2-4 wks (AI); valganciclovir 900 mg po q.d. (BI)

TABLE 2. Prophylaxis to Prevent Recurrence of Opportunistic Disease in Adults (after chemo-therapy for acute disease) in Adults and Adolescents Infected with Human Immunodeficiency Virus (continued)

Pathogen	Indication	Preventive Regimens	
		First Choice	Alternatives
<i>Cryptococcus neoformans</i>	Documented disease	Fluconazole, 200 mg po q.d. (AI)	Amphotericin B, 0.6-1.0 mg/kg iv q.w.-t.i.w. (AI); itraconazole, 200 mg capsule po q.d. (BI)
<i>Histoplasma capsulatum</i>	Documented disease	Itraconazole capsule, 200 mg po b.i.d. (AI)	Amphotericin B, 1.0 mg/kg iv q.w. (AI)
<i>Coccidioides immitis</i>	Documented disease	Fluconazole, 400 mg po q.d. (AII)	Amphotericin B, 1.0 mg/kg iv q.w. (AI); itraconazole, 200 mg capsule po b.i.d. (AII)
<i>Salmonella</i> species, (non-typhi) ³	Bacteremia	Ciprofloxacin, 500 mg po b.i.d. for several months (BII)	Antibiotic chemoprophylaxis with another active agent (CIII)
II. Recommended only if subsequent episodes are frequent or severe			
Herpes simplex virus	Frequent/severe recurrences	Acyclovir, 200 mg po t.i.d or 400 mg po b.i.d.(AI) Famciclovir 250 mg po b.i.d. (AI)	Valacyclovir, 500 mg po b.i.d. (CIII)
<i>Candida</i> (oropharyngeal or vaginal)	Frequent/severe recurrences	Fluconazole 100-200 mg po q.d. (CI)	Itraconazole solution, 200 mg po q.d. (CI);
<i>Candida</i> (esophageal)	Frequent/severe recurrences	Fluconazole 100-200 mg po q.d. (BI)	Itraconazole solution, 200 mg po q.d. (BI);

NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval. The Respigard II(TM) nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendation and the quality of evidence supporting it (see page 7). ABBREVIATIONS: b.i.d. = twice a day; DS = double-strength tablet; po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly; q.o.w. = every other week; SS = single-strength tablet; t.i.d. = three times a day; t.i.w. = three times a week; and TMP-SMZ = trimethoprim-sulfamethoxazole.

¹Pyrimethamine-sulfadiazine confers protection against PCP as well as toxoplasmosis; clindamycin-pyrimethamine does not **offer protection against PCP**.

²Many multiple-drug regimens are poorly tolerated. Drug interactions (e.g., those seen with clarithromycin and rifabutin) can be problematic; rifabutin has been associated with uveitis, especially when administered at daily doses of >300 mg or concurrently with fluconazole or clarithromycin. **See discussion of rifamycin interactions in paragraph 9 in section on Tuberculosis (54). During pregnancy, azithromycin is recommended instead of clarithromycin because clarithromycin is teratogenic in animals.**

³Efficacy for eradication of *Salmonella* has been demonstrated only for ciprofloxacin.

TABLE 3. Effects of Food on Drugs Used to Prevent Opportunistic Infections

Drug	Food Effect	Recommendation
Atovaquone	Bioavailability increased up to threefold with high-fat meal.	Administer with food.
Ganciclovir (capsules)	High-fat meal results in 22% (GCV) or 30% (VGCV) increase in AUC.	High fat meal may increase toxicity of valganciclovir
Itraconazole	Grapefruit juice results in 30% decrease in AUC.	Avoid concurrent grapefruit juice
Itraconazole (capsules)	Significant increase in bioavailability when taken with a full meal.	Administer with food.
Itraconazole (solution)	31% increase in AUC when taken under fasting conditions	Take without food if possible.

TABLE 4. Effects of Medications on Drugs used to Prevent Opportunistic Infections

Affected Drug	Interacting Drug(s)	Mechanism/Effect	Recommendation
Atovaquone	Rifampin	Induction of metabolism - decreased drug levels	Concentrations might not be therapeutic; avoid combination or increase atovaquone dose.
Atovaquone	Lopinavir-ritonavir	Potential for induction of metabolism - decreased drug levels	Concentrations may not be therapeutic - may require increase atovaquone dose, but data insufficient to make specific recommendation.
Clarithromycin	Efavirenz	Induction of metabolism - decrease in clarithromycin AUC by 39%, increase in AUC of 14-OH clarithromycin by 34%	Clarithromycin efficacy uncertain
Clarithromycin	Ritonavir	Inhibition of metabolism – increased clarithromycin drug levels by 77%	Dose adjustment of clarithromycin necessary only if renal dysfunction is present. For CrCl < 60 ml/min, reduce clarithromycin dose by 50% ; for CrCl <30 ml/min, reduce dose by 75%.
Clarithromycin	Lopinavir-Ritonavir	Inhibition of metabolism - increased clarithromycin drug levels	Dose adjustment of clarithromycin necessary only if renal dysfunction is present. For CrCl < 60 ml/min, reduce clarithromycin dose by 50% ; for CrCl <30 ml/min, reduce dose by 75%.
Clarithromycin	Nevirapine	Induction of metabolism - decrease in clarithromycin AUC by 35%, increase in AUC of 14-OH clarithromycin by 27%	Efficacy of MAC prophylaxis may be decreased; monitor closely.
Ketoconazole	Lopinavir-ritonavir	Inhibition of metabolism, increased ketoconazole AUC	Use with caution at ketoconazole doses >200 mg/day
Ketoconazole	Antacids, didanosine, (but not didanosine EC) Buffered products, H2-blockers, proton Pump inhibitors	Increase in gastric pH that impairs absorption of ketoconazole	Avoid use of ketoconazole with pH-raising agents or use alternative antifungal drug.
Quinolone antibiotics (ciprofloxacin, levofloxacin, gatifloxacin, Moxifloxacin)	Didanosine, (but not didanosine EC) antacids, iron products, calcium products, sucralfate (cation preparations)	Chelation results in marked decrease in quinolone drug levels	Administer cation preparation at least 2 hours after quinolone.

TABLE 4. Effects of Medications on Drugs used to Prevent Opportunistic Infections (continued)

Affected Drug	Interacting Drug(s)	Mechanism/Effect	Recommendation
Rifabutin	Fluconazole	Inhibition of metabolism - marked increase in rifabutin drug levels	Monitor for rifabutin toxicities such as uveitis, nausea, neutropenia.
Rifabutin	Efavirenz	Induction of metabolism - significant decrease in rifabutin AUC	Increase rifabutin dose to 450-600 mg daily or 600 mg twice weekly.*
Rifabutin	Ritonavir, lopinavir-ritonavir, ritonavir-saquinavir	Inhibition of metabolism - marked increase in rifabutin drug levels	Decrease rifabutin to 150 mg every other day or three times per week.
Rifabutin	Indinavir, nelfinavir, amprenavir	Inhibition of metabolism - marked increase in rifabutin drug levels	Decrease rifabutin to 150 mg qd or 300 mg three times per week.

* Appropriate dose of efavirenz is uncertain if a protease inhibitor is used with efavirenz plus rifabutin.

TABLE 5. Effects of Opportunistic infection Medications on Antiinfective Drugs Commonly Administered to Persons Infected with Human Immunodeficiency Virus*

Affected Drug	Interacting Drug(s)	Mechanism/Effect	Recommendation
Amprenavir, delavirdine, indinavir, lopinavir-ritonavir, nelfinavir, saquinavir	Rifampin	Induction of metabolism -- marked decrease in protease inhibitor or delavirdine drug levels	Avoid concomitant use.
Efavirenz, ritonavir, ritonavir-saquinavir, nevirapine	Rifampin	Induction of metabolism: decrease in protease or nevirapine levels	Combinations could possibly be used but limited clinical experience. Consider efavirenz 800 mg q.d. when used with rifampin
Delavirdine	Rifabutin	Induction of metabolism - 50-60% decrease in delavirdine levels	Avoid concomitant use
Indinavir, nelfinavir, amprenavir*	Rifabutin	Induction of metabolism - 50% decrease in protease inhibitor levels	Consider increase in indinavir dose to 1000 mg q8h; If indinavir is the sole protease inhibitor decrease rifabutin dose to 150 mg q.d.
Ritonavir, ritonavir-saquinavir, lopinavir-ritonavir	Rifabutin	Induction of metabolism of ritonavir	No dosage change for protease inhibitors. Consider rifabutin 150 mg q.o.d. or three times per week
Efavirenz	Rifabutin	Potential for decreased efavirenz levels	No dosage change necessary for efavirenz; adjust rifabutin dose to 450-600 mg qd or 600 mg twice weekly.
Saquinavir	Rifabutin	Potential for decreased saquinavir levels	Limited data
Didanosine	Ganciclovir (po)	Increased ddI AUC by approximately 100%	Clinical significance unknown; monitor for ddI-related adverse effects.

*Little data are available for use of rifamycin drugs with ritonavir-boosting protease inhibitor regimens except for ritonavir-saquinavir and ritonavir-lopinavir. Therefore, concomitant use of rifamycins with these regimens must be approached cautiously.

TABLE 6. Adverse Effects of Drugs Used in the Prevention of Opportunistic Infections

Bone Marrow Suppression	Cidofovir, dapsone, ganciclovir, pyrimethamine, rifabutin, sulfadiazine, TMP-SMX
Diarrhea	Atovaquone, clindamycin
Hepatotoxicity	Clarithromycin, fluconazole, isoniazid, itraconazole, ketoconazole, pyrazinamide, rifabutin, rifampin, TMP-SMX
Nephrotoxicity	Amphotericin B, cidofovir, foscarnet, pentamidine, high dose acyclovir
Ocular Effects	Cidofovir, ethambutol, rifabutin
Pancreatitis	Pentamidine, TMP-SMX
Peripheral Neuropathy	Isoniazid
Neurotoxicity	Acyclovir (high-dose), quinolones
Skin Rash	Atovaquone, dapsone, pyrimethamine , sulfadiazine, TMP-SMX, ribavirin

TABLE 7. Dosing of Drugs for Primary Prevention or Maintenance Therapy for Opportunistic Infections in Renal Insufficiency

Drug	Normal Dose	Renal Dysfunction		
		Regimen	CrCl (ml/min/1.73m ²)	Adjusted Dose
Acyclovir	200 mg - 800 mg BID - 5xday	200 mg PO TID	<10	200 mg q12h
		400 mg PO q12h	<10	200 mg q12h
		hemodialysis:		additional dose after each dialysis
Cidofovir	5 mg/kg IV every other week (with probenecid and hydration)	Reduce from 5 mg/kg to 3 mg/kg for an increase in serum creatinine of 0.3-0.4 above baseline. Discontinue for an increase in creatinine \geq 0.5 above baseline or development of 3+ proteinuria. Not recommended for patients with baseline serum creatinine > 1.5, CrCl \leq 55 ml/min, or \geq 2+ proteinuria		
Ciprofloxacin	500 mg PO q 12 hr	<u>CrCl (ml/min/1.73m²)</u>		<u>Dose</u>
		30-50		250 mg-500 mg q 12 hrs
		<30		250 mg-500 mg q 18 hrs
		hemodialysis:		250-500 mg after dialysis
Clarithromycin	500 mg BID	Reduce dose by one-half or double interval if creatinine clearance <30 ml/min		
Famciclovir	250-500 mg q 12 h	<u>CrCl</u>		<u>Dose</u>
		20-39		125-250 mg q 12 h
		<20		125-250 mg q 24 h
		hemodialysis:		125 mg after each dialysis
Fluconazole	50 mg - 400 mg qd	<u>CrCl</u>		<u>Dose</u>
		<50 (not on dialysis) dialysis		1/2 dose Full dose after dialysis

TABLE 7. Dosing of Drugs for Primary Prevention or Maintenance Therapy for Opportunistic Infections in Renal Insufficiency – continued

Foscarnet	90-120 mg/kg/day	CrCl	Maintenance	
		<u>(ml/min/kg)</u>	<u>Low Dose</u>	<u>High Dose</u>
		>1.4	90 mg q 24h	120 mg q 24 h
		1.0-1.4	70 mg q 24 h	90 mg q 24 h
		0.8-1.0	50 mg q 24 h	65 mg q 24 h
		0.6-0.8	80 mg q 48 h	104 mg q 48h
		0.5-0.6	60 mg q 48 h	80 mg q 48 h
0.4-0.5	50 mg q 48 h	65 mg q 48 h		
<0.4	not recommended	not recommended		
Ganciclovir	Oral:	<u>CrCl (ml/min)</u>	<u>IV Dose (mg/kg)</u>	<u>Capsules</u>
	1 gram TID (capsules)	50-69	2.5 q 24 h	1500 mg qd or 500 mg tid
	IV:	25-49	1.25 q 24 h	1000 mg qd or 500 mg bid
	5 mg/kg QD or 6 mg/kg QD × 5 days/week (IV)	10-24	0.625 q 24 h	500 mb qd
		<10	0.625 TIW	500 mg TIW after dialysis
Levofloxacin	250 mg-500 mg QD	<u>CrCl (ml/min)</u>	<u>Dose</u>	
		50-80	500 mg LD, then 250 mg q 24 hrs	
		<50	500 mg LD, then 250 mg q 48 hrs	
TMP/SMX	1 DS QD	<u>CrCl (ml/min)</u>	<u>Dose</u>	
	1 DS TIW	15-30	1/2 dose	
	1 SS QD	<15	1/2 dose or use alternative agent	
Valacyclovir	500 mg-1 gm q 24 h	<u>CrCl (ml/min/1.73m²)</u>	<u>Dose</u>	
		<30	500 mg q 24-48 h	
Valganciclovir	900 mg qd	<u>CrCl</u>	<u>Dose</u>	
		40-59	450 mg qd	
		25-39	450 mg qd	
		10-24	450 mg twice weekly	
		<10	not recommended	
	Dialysis	not recommended		

ABBREVIATIONS: b.i.d. = twice daily; CrCl = creatinine clearance; DS = double-strength tablet; iv = intravenous; l.d. = loading dose; q.d. = daily; q.o.w. = every other week; SS = single-strength tablet; t.i.d. = three times daily; t.i.w. = three times a week.

*Creatinine clearance for foscarnet is expressed as ml/min/kg.

TABLE 8. Wholesale Acquisition Costs of Agents Recommended for the Prevention of Opportunistic Infections in Adults Infected with Human Immunodeficiency Virus

Opportunistic Pathogen	Drug/Vaccine	Dose	Annual Cost Per Patient
<i>Pneumocystis carinii</i>	Trimethoprim-Sulfamethoxazole	160/800 mg q.d.	\$ 135
	Dapsone	100 mg q.d.	\$72
	Aerosolized pentamidine	300 mg q.m.	\$1,185
	Atovaquone	1500 mg q.d.	\$11,627
<i>Mycobacterium avium</i> complex	Clarithromycin	500 mg b.i.d.	\$ 2,843
	Azithromycin	1,200 mg q.w.	\$ 3,862
	Rifabutin	300 mg q.d.	\$3,352
Cytomegalovirus	Ganciclovir (po)	1,000 mg t.i.d.	\$17,794
	Ganciclovir implant*		\$5,000
	Ganciclovir (iv)	5mg/kg q.d.	\$13,093
	Foscarnet (iv)	90-120 mg/kg q.d.	\$27,770-37,027
	Cidofovir (iv)	375 mg q.o.w.	\$20,904
	Fomivirsen (intravitreal)	1 vial every 4 wks	\$12,000
	Valganciclovir	900 mg q.d.	\$21,582
<i>Mycobacterium tuberculosis</i>	Isoniazid [†]	300 mg q.d.	\$23 (9 months)
	Rifampin	600 mg q.d.	\$294 (2 months)
	Pyrazinamide	1,500 mg q.d.	\$194 (2 months)
Fungi	Fluconazole	200 mg q.d.	\$4,603
	Itraconazole capsules	200 mg q.d.	\$5,340
	Itraconazole solution	200 mg q.d.	\$5,673
	Ketoconazole	200 mg q.d.	\$1,230
Herpes simplex virus	Acyclovir	400 mg b.i.d.	\$1,384
	Famciclovir	500 mg b.i.d.	\$5,311
	Valacyclovir	500 mg b.i.d.	\$2,538
<i>Toxoplasma gondii</i>	Pyrimethamine	50 mg q.w.	\$ 49
	Leucovorin	25 mg q.w.	\$ 988
	Sulfadiazine	500 mg q.i.d.	\$1,490
<i>Streptococcus pneumoniae</i>	23-valent pneumococcal vaccine	0.5 ml im x 1	\$13
Influenza virus	Inactivated trivalent influenza vaccine	0.5 ml im x 1	\$ 3
Hepatitis A virus	Hepatitis A vaccine	1.0 ml im x 2	\$ 124
Hepatitis B virus	Recombinant hepatitis B	10-20µg im x 3	\$70
Bacterial infections	G-CSF	300 µg t.i.w.	\$29,406
Varicella zoster virus	VZIG	5 vials (6.25 ml)	\$ 562

ABBREVIATIONS: b.i.d. = twice daily; G-CSF = granulocyte-colony-stimulating factor; iv = intravenous; im = intramuscular; po = by mouth; q.d. = daily; q.o.w. = every other week; q.w. = once a week; ; t.i.d. = three times daily; t.i.w. = three times a week; VZIG = varicella zoster immune globulin.

*Implant generally lasts 6-9 months.

[†]Cost for 9 months of therapy.

Source: Medical Economics. Drug topics red book. Montvale, New Jersey: Medical Economics Inc., 2000.

TABLE 9. Immunologic Categories for Human Immunodeficiency Virus-infected Children Based on Age-specific CD4+ T-lymphocyte Counts and Percentage of Total Lymphocytes*

Immunologic Category	Age		
	<u>≤12 months</u> cells/μL (%)	<u>1-5 years</u> cells/μL (%)	<u>6-12 years</u> cells/μL (%)
1. No evidence of suppression	≥1,500 (≥25)	≥1,000 (≥25)	≥500 (≥25)
2. Evidence of moderate suppression	750-1,499 (15-24)	500-999 (15-24)	200-499 (15-24)
3. Severe suppression	<750 (<15)	<500 (<15)	<200 (<15)

*Adapted from CDC. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(No. RR-12). (123).

TABLE 10. Recommended Immunization Schedule for Human Immunodeficiency Virus-infected Children^a

Vaccine	Age															
	Birth	1 mo	2 mos	4 mos	6 mos	12 mos	15 mos	18 mos	24 mos	4-6 yrs	11-12 yrs	14-16 yrs				
Recommendations for these vaccines are the same as those for immunocompetent children.																
Hepatitis B ¹	Hep B #1		Hep B #2			Hep B #3										
Diphtheria and Tetanus toxoids, Pertussis ²			DTaP	DTaP	DTaP		DTaP			DTaP		Td				
Haemophilus influenzae type b ³			Hib	Hib	Hib		Hib									
Inactivated Polio ⁴			IPV	IPV	IPV					IPV						
Hepatitis A ⁵									Hep A in selected areas							
Recommendations for these vaccines differ from those for immunocompetent children.																
Pneumococcus ⁶			PCV	PCV	PCV		PCV			PPV23						
Measles, Mumps, Rubella ⁷	Do not give to severely immunosuppressed (Category 3) children. Give only to asymptomatic non-immunosuppressed (category 1) children. Contraindicated in all other HIV infected children.						MMR			MMR		MMR				
Varicella ⁸								Var	Var							Var
Influenza ⁹								A dose is recommended every year								

Range of recommended ages for vaccination.

Vaccines to be given if previously recommended doses were missed or were given earlier than the recommended minimum age.

Recommended in selected states and/or regions.

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines as of November 1, 2000, for children through age 18 years. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine's other components are not contraindicated. Providers should consult the manufacturer's package inserts for detailed recommendations.

1. Infants born to hepatitis B surface antigen (HBsAg)- negative mothers should receive the first dose of hepatitis B vaccine (Hep B) at birth and no later than age 2 months. The second dose should be administered at least 1 month after the first dose. The third dose should be administered at least 4 months after the first dose and at least 2 months after the second dose, but not before age 6 months. **Infants born to HBsAg- positive mothers** should receive Hep B and 0.5 mL hepatitis B immune globulin (HBIG) within 12 hours of birth at separate sites. The second dose is recommended at age 1– 2 months and the third dose at age 6 months. **Infants born to mothers whose HBsAg status is unknown** should receive Hep B within 12 hours of birth. Maternal blood should be drawn at delivery to determine the mother's HBsAg status; if the HBsAg test is positive, the infant should receive HBIG as soon as possible (no later than age 1 week). **All children and adolescents (through age 18 years)** who have not been immunized against hepatitis B should begin the series during any visit. Providers should make special efforts to immunize children who were born in or whose parents were born in areas of the world where hepatitis B virus infection is moderately or highly endemic.

2. The fourth dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) may be administered as early as age 12 months, provided 6 months have elapsed since the third dose and the child is unlikely to return at age 15– 18 months. Tetanus and diphtheria toxoids (Td)

is recommended at age 11– 12 years if at least 5 years have elapsed since the last dose of diphtheria and tetanus toxoids and pertussis vaccine (DTP), DTaP, or diphtheria and tetanus toxoids (DT). Subsequent routine Td boosters are recommended every 10 years.

3. Three Haemophilus influenzae type b (Hib) conjugate vaccines are licensed for infant use. If Hib conjugate vaccine (PRP- OMP) (PedvaxHIB or ComVax [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required. Because clinical studies in infants have demonstrated that using some combination products may induce a lower immune response to the Hib vaccine component, DTaP/ Hib combination products should not be used for primary immunization in infants at ages 2, 4 or 6 months unless approved by the Food and Drug Administration for these ages.

4. An all- inactivated poliovirus vaccine (IPV) schedule is recommended for routine childhood polio vaccination in the United States. All children should receive four doses of IPV at age 2 months, age 4 months, between ages 6 and 18 months, and between ages 4 and 6 years. Oral poliovirus vaccine should not be administered to HIV infected persons or their household contacts.

5. Hepatitis A vaccine (Hep A) is recommended for use in selected states and/ or regions, and for certain high- risk groups such as those with Hepatitis B or Hepatitis C infection. Information is available from local public health authorities.

6. **The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children age 2-59 months with HIV. Children 2 years and older should also receive the 23 valent pneumococcal polysaccharide vaccine; a single revaccination with the 23 valent vaccine should be offered to children after 3-5 years. Refer to the Advisory Committee on Immunization Practices recommendations (80) on dosing intervals for children starting the vaccination schedule after 2 months of age.**

7. MMR should not be administered to severely immunocompromised (**category 3**) children. HIV infected children without severe immunosuppression would routinely receive their first dose of MMR as soon as possible after reaching their first birthday. Consideration should be given to administering the second dose of MMR as soon as 1 month (i.e., a minimum of 28 days) after the first dose rather than waiting until school entry.

8. **Varicella zoster virus vaccine should be given only to asymptomatic, nonimmunosuppressed children. Eligible children should receive two doses of vaccine with at least a 3-month interval between doses. The first dose may be given as early as 12 months of age.**

9. **Inactivated split influenza virus vaccine should be administered to all HIV infected children \geq 6 months of age each year.**

For children aged 6 months to <9 years who are receiving influenza vaccine for the first time, two doses given \geq 1 month apart are recommended. For specific recommendations, see: CDC. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2001;50:RR-4.

TABLE 11. Prophylaxis to Prevent First Episode of Opportunistic Disease in Infants and Children Infected with Human Immunodeficiency Virus

Pathogen	Preventive Regimens		
	Indication	First Choice	Alternatives
1. Strongly recommended as standard of care			
<i>Pneumocystis carinii</i> ¹	<p>HIV-infected or HIV-indeterminate, infants aged 1-12 mo;</p> <p>HIV-infected children aged 1-5 yr with CD4+ count <500/μL or CD4+ percentage <15%;</p> <p>HIV-infected children aged 6-12 yr with CD4+ count <200/μL or CD4+percentage <15%</p>	<p>Trimethoprim-sulfamethoxazole (TMP-SMZ), 150/750 mg/m²/d in 2 divided doses po t.i.w. on consecutive days (AII)</p> <p>Acceptable alternative dosage schedules: (AII)</p> <p>•Single dose po t.i.w. on consecutive days;</p> <p>•2 divided doses po q.d.; 2 divided doses po t.i.w. on alternate days</p>	<p>Dapsone (children aged ≥1 mo), 2mg/kg (max 100 mg) po q.d. or 4 mg/kg (max 200 mg) po q.w. (CII); aerosolized pentamidine (children aged ≥5 yr), 300 mg q.m. via Respigard II™ nebulizer (CIII); atovaquone (children aged 1-3 mo. and >24 mo., 30mg/kg po q.d.; children aged 4-24 mo., 45 mg/kg po q.d.) (CII)</p>
<i>Mycobacterium tuberculosis</i> ² Isoniazid-sensitive	TST reaction, ≥5mm or prior positive TST result without treatment; or contact with any case of active tuberculosis regardless of TST result	Isoniazid 10-15 mg/kg (max 300 mg) po q.d. x 9 mo (AII) or 20-30 mg/kg (max 900) mg po biw x 9 months (BII)	Rifampin, 10-20 mg/kg (max 600 mg) po q.d. x 4-6 mo (BIII)
Isoniazid-resistant	Same as above; high probability of exposure to isoniazid-resistant tuberculosis	Rifampin, 10-20 mg/kg (max 600 mg) po q.d. x 4-6 mo (BIII)	Uncertain
Multidrug-(isoniazid and rifampin) resistant	Same as above; high probability of exposure to multi-drug resistant tuberculosis	Choice of drugs requires consultation with public health authorities and depends on susceptibility of isolate from source patient	
<i>Mycobacterium avium</i> complex ²	For children aged ≥6 yrs, CD4+ count <50/μL; aged 2-6 yrs CD4+ count <75/μL; aged 1-2 yrs, CD4+ count <500/μL; aged <1 yr, CD4+ count <750/μL	Clarithromycin 7.5 mg/kg (max 500 mg) po b.i.d. (AII), or azithromycin, 20 mg/kg (max 1,200 mg) po q.w. (AII)	Azithromycin, 5 mg/kg (max 250 mg) po q.d. (AII); children aged ≥6 yrs, rifabutin, 300 mg po q.d. (BI)
Varicella zoster virus ³	Significant exposure to varicella or shingles with no history of chickenpox or shingles	Varicella zoster immune globulin (VZIG), 1 vial (1.25 mL)/10 kg (max 5 vials) im, administered ≤96 hrs after exposure, ideally within 48 hrs (AII)	None

TABLE 11. Prophylaxis to Prevent First Episode of Opportunistic Disease in Infants and Children Infected with Human Immunodeficiency Virus - continued

Preventive Regimens

Pathogen	Indication	First Choice	Alternatives
Vaccine-preventable Pathogens ⁴	HIV exposure/infection	Routine immunizations (see Table 10)	None
II. Generally recommended <i>Toxoplasma gondii</i> ⁵	IgG antibody to <i>Toxoplasma</i> and severe immunosuppression	TMP-SMZ, 150/750 mg/m ² /d in 2 divided doses po q.d. (BIII)	Dapsone (children aged ≥1 mo), 2mg/kg or 15 mg/m ² (max 25 mg) po q.d. <i>plus</i> pyrimethamine, 1 mg/kg po q.d. <i>plus</i> leucovorin, 5 mg po every 3 days (BIII) Atovaquone, (aged 1-3 mo. and >24 mo., 30 mg/kg po q.d.; aged 14-24 mo. 45 mg/kg po q.d.) (CIII)
Varicella zoster virus	HIV-infected children who are asymptomatic and not immunosuppressed	Varicella zoster vaccine (see vaccine-preventable pathogens section of this table) (BII)	None
Influenza virus	All patients (annually, before influenza season)	Inactivated split trivalent influenza vaccine (see vaccine-preventable section of this table) (BIII)	Oseltamivir (during outbreaks of influenza A or B) for children ≥ 13 years, 75 mg po q.d. (CIII); rimantadine or amantadine (during outbreaks of influenza A); aged 1-9 yr, 5 mg/kg in 2 divided doses (max 150 mg/day) po q.d.; aged ≥10 yr, use adult doses (CIII).
III. Not recommended for most children; indicated for use only in unusual circumstances			
Invasive bacterial infections ⁶	Hypogammaglobulinemia (i.e., IgG <400 mg/dL)	IVIG (400mg/kg every 2-4 wks) (AI)	None
<i>Cryptococcus neoformans</i>	Severe immunosuppression	Fluconazole, 3-6 mg/kg po q.d. (CII)	Itraconazole, 2-5 mg/kg po every 12-24 h (CII)
<i>Histoplasma capsulatum</i>	Severe immunosuppression, endemic geographic area	Itraconazole, 2-5 mg/kg po every 12-24 h (CIII)	None
Cytomegalovirus (CMV) ⁷	CMV antibody positivity and severe immunosuppression	Oral ganciclovir 30 mg/kg po t.i.d. (CII)	None

NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval. The Respirgard II™ nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendation and the quality of the evidence supporting it (see page 7).

ABBREVIATIONS: b.i.w. = twice a week; IVIG = intravenous immune globulin; q.d. = daily; q.m. = monthly; t.i.d. = three times a day; t.i.w. = three times a week.

¹Daily TMP-SMZ reduces the frequency of some bacterial infections. TMP-SMZ, dapsone-pyrimethamine, and possibly atovaquone (with or without pyrimethamine) appear to protect against toxoplasmosis, although data have not been prospectively collected. When compared with weekly dapsone, daily dapsone is associated with lower incidence of *Pneumocystis carinii* pneumonia (PCP) but higher hematologic toxicity and mortality (McIntosh K, Cooper E, Xu J, et al. **Toxicity and Efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with HIV. Ped Infect Dis J 1999;18:432-9).**

The efficacy of parenteral pentamidine (e.g., 4 mg/kg q 2-4 wks) is controversial. Patients receiving therapy for toxoplasmosis with sulfadiazine-pyrimethamine are protected against PCP and do not need TMP-SMZ.

²Significant drug interactions can occur between rifamycins (rifampin and rifabutin) and protease inhibitors and nonnucleoside reverse transcriptase inhibitors. Consult a specialist.

³Children routinely being administered intravenous immune globulin (IVIG) should receive VZIG if the last dose of IVIG was administered >21 days before exposure.

⁴HIV-infected and HIV-exposed children should be immunized according to the childhood immunization schedule in this report (Table 10), which has been adapted from the January-December **2001** schedule recommended for immunocompetent children by the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians. This schedule differs from that for immunocompetent children in that **both the conjugate pneumococcal vaccine (PCV-7) and the pneumococcal polysaccharide vaccine (PPV-23) are recommended (BII) and vaccination against influenza (BIII) should be offered.** MMR should not be administered to severely immunocompromised children (DIII). Vaccination against varicella is indicated only for asymptomatic nonimmunosuppressed children (BII). Once an HIV-exposed child is determined not to be HIV infected, the schedule for immunocompetent children applies.

⁵Protection against toxoplasmosis is provided by the preferred antipneumocystis regimens and possibly by atovaquone. Atovaquone may be used with or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection (for definition of severe immunosuppression, see Table 9).

⁶Respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted for IVIG during the RSV season to provide broad antiinfective protection, if this product is available.

⁷Oral ganciclovir and perhaps valganciclovir results in reduced CMV shedding in CMV-infected children. Acyclovir is not protective against CMV.

TABLE 12. Prophylaxis to Prevent Recurrence of Opportunistic Disease (after chemotherapy for acute disease) in HIV-infected Infants and Children

Preventive Regimens			
Pathogen	Indication	First Choice	Alternatives
I. Recommended for life as standard of care			
<i>Pneumocystis carinii</i>	Prior <i>P. carinii</i> pneumonia	TMP-SMZ, 150/750 mg/m ² /d in 2 divided doses po t.i.w. on consecutive days (AII) Acceptable alternative schedules for same dosage: (AII) Single dose po t.i.w. on consecutive days; 2 divided doses po q.d; 2 divided doses po t.i.w. on alternate days	Dapsone (children aged ≥1 mo), 2 mg/kg (max 100 mg) po q.d. or 4 mg/kg (max 200 mg) po q.w. (CII); aerosolized pentamidine (children aged ≥5 yrs), 300 mg q.m. via Respigard II™ nebulizer (CIII); atovaquone (aged 1-3 months and >24 mo., 30 mg/kg po q.d.; aged 4-24 mo., 45 mg/kg po q.d.) (CII)
<i>Toxoplasma gondii</i> ¹	Prior toxoplasmic encephalitis	Sulfadiazine, 85-120 mg/kg/d in 2-4 divided doses po q.d. <i>plus</i> pyrimethamine, 1 mg/kg or 15 mg/m ² (max 25 mg) po q.d. <i>plus</i> leucovorin, 5 mg po every 3 days (AI)	Clindamycin, 20-30 mg/kg/d in 4 divided doses po q.d. <i>plus</i> pyrimethamine, 1 mg/kg po q.d. <i>plus</i> leucovorin, 5 mg po every 3 days (BI)
<i>Mycobacterium avium</i> Complex ²	Prior disease	Clarithromycin, 7.5 mg/kg (max 500 mg) po b.i.d. (AII) <i>plus</i> ethambutol, 15 mg/kg (max 900 mg) po q.d. (AII); with or without rifabutin, 5 mg/kg (max 300 mg) po q.d. (CII)	Azithromycin, 5 mg/kg (max 250 mg) po q.d. (AII) <i>plus</i> ethambutol, 15 mg/kg (max 900 mg) po q.d. (AII); with or without rifabutin, 5 mg/kg (max 300 mg) po q.d. (CII)
<i>Cryptococcus neoformans</i>	Documented disease	Fluconazole, 3-6 mg/kg po q.d. (AII)	Amphotericin B, 0.5-1.0 mg/kg iv 1-3x/week (AI); itraconazole, 2-5 mg/kg po every 12-24h (BII).
<i>Histoplasma capsulatum</i>	Documented disease	Itraconazole, 2-5 mg/kg po every 12-48 h (AIII)	Amphotericin B, 1.0 mg/kg iv q.w. (AIII)
<i>Coccidioides immitis</i>	Documented disease	Fluconazole, 6 mg/kg po q.d. (AIII)	Amphotericin B, 1.0 mg/kg iv q.w. (AIII); itraconazole, 2-5 mg/kg po every 12-48 h (AIII)
Cytomegalovirus	Prior end-organ disease	Ganciclovir, 5 mg/kg iv q.d.; or foscarnet, 90-120 mg/kg iv q.d. (AI)	(For retinitis) Ganciclovir sustained-release implant every 6-9 mo. <i>Plus</i> ganciclovir, 30 mg/kg po t.i.d. (BIII)

TABLE 12. Prophylaxis to Prevent Recurrence of Opportunistic Disease (after chemotherapy for acute disease) in HIV-infected Infants and Children - continued

Preventive Regimens			
Pathogen	Indication	First Choice	Alternatives
<i>Salmonella</i> species (non-typhi) ³	Bacteremia	TMP-SMZ, 150/750 mg/m ² in 2 divided doses po q.d. for several months (CIII)	Antibiotic chemoprophylaxis with another active agent (CIII)
II. Recommended only if subsequent episodes are frequent or severe			
Invasive bacterial Infections ⁴	>2 infections in 1-year period	TMP-SMZ, 150/750 mg/m ² , in 2 divided doses po q.d. (BI); or IVIG, 400 mg/kg every 2-4 wks. (BI)	Antibiotic chemoprophylaxis with another active agent (BIII)
Herpes simplex virus	Frequent/severe recurrences	Acyclovir, 80 mg/kg/d in 3-4 divided doses po q.d. (AII)	
<i>Candida</i> (oropharyngeal)	Frequent/severe recurrences	Fluconazole, 3-6 mg/kg po q.d. (CIII)	
<i>Candida</i> (esophageal)	Frequent/severe recurrences	Fluconazole, 3-6 mg/kg po q.d. (BIII)	Itraconazole solution, 5 mg/kg po q.d. (CIII);

NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" might not be synonymous with the FDA-defined legal standards for product approval. The Respirgard IITM nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendations and the quality of evidence supporting it (see page 7).

ABBREVIATIONS: IVIG = intravenous immune globulin; po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly; t.i.d. = three times a day; t.i.w. = three times a week; and TMP-SMZ = trimethoprim-sulfamethoxazole.

¹Only pyrimethamine plus sulfadiazine confers protection against PCP as well as toxoplasmosis. Although the clindamycin plus pyrimethamine regimen is recommended in adults, it has not been tested in children. However, these drugs are safe and are used for other infections.

²Significant drug interactions might occur between rifabutin and protease inhibitors and nonnucleoside reverse transcriptase inhibitors. Consult an expert.

³Drug should be determined by susceptibilities of the organism isolated. Alternatives to TMP-SMZ include ampicillin, chloramphenicol, or ciprofloxacin. However, ciprofloxacin is not approved for use in persons aged <18 years; therefore, it should be used in children with caution and only if no alternatives exist.

⁴Antimicrobial prophylaxis should be chosen based on the microorganism and antibiotic sensitivities. TMP-SMZ, if used, should be administered daily. Providers should be cautious about using antibiotics solely for this purpose because of the potential for development of drug-resistant microorganisms. IVIG might not provide additional benefit to children receiving daily TMP-SMZ but may be considered for children who have recurrent bacterial infections despite TMP-SMZ prophylaxis. Choice of antibiotic prophylaxis vs. IVIG should also involve consideration of adherence, ease of intravenous access, and cost. If IVIG is used, respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted for IVIG during the RSV season to provide broad anti-infective protection, if this product is available.

Table 13. Criteria for **Starting, Discontinuing**, and Restarting Opportunistic Infection Prophylaxis for Adults with human Immunodeficiency Virus Infection*

	Criteria for Initiating Primary Prophylaxis	Criteria for Discontinuing Primary Prophylaxis	Criteria for Restarting Primary Prophylaxis	Criteria for Initiating Secondary Prophylaxis	Criteria for Discontinuing Secondary Prophylaxis	Criteria for Restarting Secondary Prophylaxis
Opportunistic Illness						
<i>Pneumocystis carinii</i> pneumonia	CD4+ <200 cells/μL or oropharyngeal candidiasis (AI)	CD4+ >200 cells/μL for ≥3 months (AI)	CD4+ <200 cells/μL (AIII)	Prior <i>Pneumocystis carinii</i> pneumonia (AI)	CD4+ >200 cells/μL for ≥3 months (BII)	CD4+ <200 cells/μL (AIII)
Toxoplasmosis	IgG antibody to toxoplasma and CD4+ <100 cells/μL (AI)	CD4+ >200 cells/μL for ≥3 months (AI)	CD4+ <100-200 cells/μL (AIII)	Prior toxoplasmic encephalitis (AI)	<ul style="list-style-type: none"> •CD4+ >200 cells/μL sustained (e.g., ≥6 months) and •Completed initial therapy and •Asymptomatic for toxo (CIII) 	CD4+ <200 cells/μL (AIII)
Disseminated <i>Mycobacterium avium</i> complex	CD4+ <50 cells/μL (AI)	CD4+ >100 cells/μL for ≥3 months (AI)	CD4+ <50-100 cells/μL (AIII)	Documented disseminated disease (AII)	<ul style="list-style-type: none"> •CD4+ >100 cells/μL sustained (e.g., ≥6 months) and *Completed 12 months of MAC therapy and *Asymptomatic for MAC (CIII) 	CD4+ <100 cells/μL (AIII)
Cryptococcosis	None	Not applicable	Not applicable	Documented disease (AI)	<ul style="list-style-type: none"> •CD4+ >100-200 cells/μL sustained (e.g., ≥6 months) and •Completed initial therapy and •Asymptomatic for cryptococcosis (CIII) 	CD4+ <100-200 cells/μL (AIII)
Histoplasmosis	None	Not applicable	Not applicable	Documented disease (AI)	No criteria recommended for stopping	Not applicable
Coccidioidomycosis	None	Not applicable	Not applicable	Documented disease (AI)	No criteria recommended for stopping	Not applicable
Cytomegalovirus retinitis	None	Not applicable	Not applicable	Documented end-organ disease (AI)	<ul style="list-style-type: none"> •CD4+ >100-150 cells/μL sustained (e.g., ≥6 months) and • No evidence of active disease • Regular ophthalmic examination (BII) 	CD4+ <100-150 cells/μL (AIII)

APPENDIX. Recommendations to Help Patients Avoid Exposure to or Infection with Opportunistic Pathogens*

SEXUAL EXPOSURES

1. Patients should use a latex condom during every act of sexual intercourse to reduce the risk for acquiring cytomegalovirus, herpes simplex virus, and human papillomavirus, as well as other sexually transmitted pathogens (AII). Condom use also will, theoretically, reduce the risk for acquiring human herpesvirus 8, as well as superinfection with an HIV strain that has become resistant to antiretroviral drugs (BIII) and will prevent transmission of HIV and other sexually transmitted pathogens to others (AII). Data regarding the use and efficacy of female condoms are incomplete, but these devices should be considered as a risk-reduction strategy (BIII).

2. Patients should avoid sexual practices that might result in oral exposure to feces (e.g., oral-anal contact) to reduce the risk for intestinal infections (e.g., cryptosporidiosis, shigellosis, campylobacteriosis, amebiasis, giardiasis, and hepatitis A (BIII)). **Latex condom use alone may not reduce the risk of acquiring these fecal-orally transmitted pathogens, especially those which have low infectious doses. Persons wishing to reduce their risk of exposure might consider using dental dams or similar barrier methods for oral-anal and oral-genital contact, changing condoms after anal intercourse, and wearing latex gloves during digital-anal contact. Frequently washing hands and genitals with warm soapy water during and after activities which may bring these body parts in contact with feces may further reduce risk of illness. (CIII).**

3. **Hepatitis B immunizations is recommended for all susceptible (anti-HBc-negative) HIV-infected patients (BII).**

4. **Hepatitis A immunization is recommended for all susceptible men who have sex with men, as well as others with indications for HAV vaccine (BIII).**

INJECTION DRUG USE EXPOSURES

1. Injection drug use is a complex behavior that puts HIV-infected persons at risk for **hepatitis B virus and hepatitis C virus** infection, additional, possibly drug-resistant strains of HIV, and other blood-borne pathogens. Providers should assess the individual's readiness to change this practice and encourage efforts to provide education and support directed at recovery. Patients should be counseled to stop using injection drugs (AIII) and to enter and complete substance-abuse treatment, including relapse prevention programs (AIII).

2. If they are continuing to inject drugs, patients should be advised (BIII)

- to never reuse or share syringes, needles, water, or drug preparation equipment; if, nonetheless, injection equipment that has been used by other persons is shared, to first clean the equipment with bleach and water (U.S. Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs. May 8, 1997. Rockville, Maryland: CDC, 1997);
- to use only sterile syringes obtained from a reliable source (e.g., pharmacies or syringe exchange programs);
- to use sterile (e.g., boiled) water to prepare drugs; if not possible, to use clean water from a reliable source (e.g., fresh tap water); to use a new or disinfected container ("cooker") and a new filter ("cotton") to prepare drugs;
- to clean the injection site with a new alcohol swab before injection;
- to safely dispose of syringes after one use.

3. **All susceptible injection drug users should be immunized against hepatitis B (BII) and hepatitis A (BIII).**

*Letters and Roman numerals in parentheses indicate the strength of the recommendation and the quality of evidence supporting it (see Box, page 3).

ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES

1. Certain activities or types of employment might increase the risk for exposure to tuberculosis (BIII). These include volunteer work or employment in health-care facilities, correctional institutions, and shelters for the homeless, as well as other settings identified as high risk by local health authorities. Decisions about whether to continue with such activities should be made in conjunction with the health-care provider and should be based on such factors as the patient's specific duties in the workplace, the prevalence of tuberculosis in the community, and the degree to which precautions designed to prevent the transmission of tuberculosis are taken in the workplace (BIII). These decisions will affect the frequency with which the patient should be screened for tuberculosis.

2. Child-care providers and parents of children in child care are at increased risk for acquiring CMV infection, cryptosporidiosis, and other infections (e.g., hepatitis A and giardiasis) from children. The risk for acquiring infection can be diminished by good hygienic practices, such as hand washing after fecal contact (e.g., during diaper changing) and after contact with urine or saliva (AII). All children in child-care facilities also are at

increased risk for acquiring these same infections; parents and other caretakers of HIV-infected children should be advised of this risk (BIII).

3. Occupations involving contact with animals (e.g., veterinary work and employment in pet stores, farms, or slaughterhouses) might pose a risk for cryptosporidiosis, toxoplasmosis, salmonellosis, campylobacteriosis, or *Bartonella* infection. However, the available data are insufficient to justify a recommendation against work in such settings.

4. Contact with young farm animals, especially animals with diarrhea, should be avoided to reduce the risk for cryptosporidiosis (BII).

5. Hand washing after gardening or other contact with soil might reduce the risk for cryptosporidiosis and toxoplasmosis (BIII).

6. In areas endemic for histoplasmosis, patients should avoid activities known to be associated with increased risk (e.g., creating dust when working with surface soil; cleaning chicken coops that are heavily contaminated with compost droppings; disturbing soil beneath bird-roosting sites; cleaning, remodeling or demolishing old buildings; and cave exploring) (CIII).

7. In areas endemic for coccidioidomycosis, when possible, patients should avoid activities associated with increased risk, including those involving extensive exposure to disturbed native soil (e.g., at building excavation sites or during dust storms) (CIII).

PET-RELATED EXPOSURES

Health-care providers should advise HIV-infected persons of the potential risk posed by pet ownership. However, they should be sensitive to the possible psychological benefits of pet ownership and should not routinely advise HIV-infected persons to part with their pets (DIII). Specifically, providers should advise HIV-infected patients of the following precautions. 62 MMWR August 20, 1999

General

1. Veterinary care should be sought when a pet develops diarrheal illness. If possible, HIV-infected persons should avoid contact with animals that have diarrhea (BIII). A fecal sample should be obtained from animals with diarrhea and examined for *Cryptosporidium*, *Salmonella*, and *Campylobacter*.

2. When obtaining a new pet, HIV-infected patients should avoid animals aged <6 months (or < 1 year for cats; see Cats section, which follows), especially those with diarrhea (BIII). Because the hygienic and sanitary conditions in pet-breeding facilities, pet stores, and animal shelters are highly variable, the patient should be cautious when obtaining a pet from these sources. Stray animals should be avoided. Animals aged <6 months, especially those with diarrhea, should be examined by a veterinarian for *Cryptosporidium*, *Salmonella*, and *Campylobacter* (BIII).

3. Patients should wash their hands after handling pets (especially before eating) and avoid contact with pets' feces to reduce the risk for cryptosporidiosis, salmonellosis, and campylobacteriosis (BIII). Hand washing for HIV-infected children should be supervised.

Cats

4. Patients should be aware that cat ownership increases their risk for toxoplasmosis and *Bartonella* infection, as well as enteric infections (CIII). Those who elect to obtain a cat should adopt or purchase an animal that is aged >1 year and in good health to reduce the risk for cryptosporidiosis, *Bartonella* infection, salmonellosis, and campylobacteriosis (BII).

5. Litter boxes should be cleaned daily, preferably by an HIV-negative, nonpregnant person; if the HIV-infected patient performs this task, he or she should wash hands thoroughly afterward to reduce the risk for toxoplasmosis (BIII).

6. To reduce the risk for toxoplasmosis, HIV-infected patients should keep cats indoors, not allow them to hunt, and not feed them raw or undercooked meat (BIII).

7. Although declawing is not generally advised, patients should avoid activities that might result in cat scratches or bites to reduce the risk for *Bartonella* infection (BII). Patients should also wash sites of cat scratches or bites promptly (CIII) and should not allow cats to lick the patients' open cuts or wounds (BIII).

8. Care of cats should include flea control to reduce the risk for *Bartonella* infection (CIII).

9. Testing cats for toxoplasmosis (EII) or *Bartonella* infection (DII) is not recommended.

Birds

10. Screening healthy birds for *Cryptococcus neoformans*, *Mycobacterium avium*, or *Histoplasma capsulatum* is not recommended (DIII).

Other

11. Contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) **as well as chicks and ducklings** should be avoided to reduce the risk for salmonellosis (BIII).
12. Gloves should be used during the cleaning of aquariums to reduce the risk for infection with *Mycobacterium marinum* (BIII).
13. Contact with exotic pets (e.g., nonhuman primates) should be avoided (CIII).

FOOD AND WATER-RELATED EXPOSURES

1. Raw or undercooked eggs (including foods that might contain raw eggs [e.g., some preparations of hollandaise sauce, Caesar and certain other salad dressings, **some mayonnaises, uncooked cookie and cake batter, egg nog**]); raw or undercooked poultry, meat, seafood (**especially raw shellfish**); and unpasteurized dairy products; **unpasteurized fruit juice; and raw seed sprouts (e.g., alfalfa sprouts, mung bean sprouts)**. Poultry and meat are safest when adequate cooking is confirmed with a thermometer (internal temperature of **180° F for poultry and 165° F for red meats**). **If a thermometer is not used, the risk of illness is decreased by consuming poultry and meat that have no trace of pink. Color change of the meat (e.g., absence of pink) does not always correlate with internal temperature.** Produce should be washed thoroughly before being eaten (BIII).

2. Cross-contamination of foods should be avoided. Uncooked meats should not be allowed to come in contact with other foods; hands, cutting boards, counters, and knives and other utensils should be washed thoroughly after contact with uncooked foods (BIII).

3. Although the incidence of listeriosis is low, it is a serious disease that occurs unusually frequently among HIV-infected persons who are severely immunosuppressed. **An immunosuppressed, HIV-infected person who wishes to reduce the risk of acquiring listeriosis as much as possible may choose to do the following:**

1) avoid soft cheeses (e.g., feta, Brie, Camembert, blue-veined and Mexican-style cheese such as queso fresco). Hard cheeses, processed cheeses, cream cheese (including slices and spreads), cottage cheese, or yogurt need not be avoided;

2) cook leftover foods or ready-to-eat foods (e.g., hot dogs) until steaming hot before eating;

3) avoid foods from delicatessen counters (e.g., prepared salads, meats, cheeses) or heat/reheat these foods until steaming before eating;

4) avoid refrigerated pates and other meat spreads, or heat/reheat these foods until steaming if eaten.

Canned or shelf-stable pate and meat spreads need not be avoided;

5) avoid raw or unpasteurized milk (including goat's milk) or milk-products, or foods which contain unpasteurized milk or milk-products. (CIII).

4. Patients should not drink water directly from lakes or rivers because of the risk for cryptosporidiosis and giardiasis (AIII). Waterborne infection might also result from swallowing water during recreational activities. Patients should avoid swimming in water that is likely to be contaminated with human or animal waste and should avoid swallowing water during swimming (BII).

5. During outbreaks or in other situations in which a community "boil water advisory" is issued, boiling water for 1 minute will eliminate the risk for acquiring cryptosporidiosis (AI). Using submicron, personal-use water filters (home/office types) and/or drinking bottled water might also reduce the risk (see Cryptosporidiosis section in Disease-Specific Recommendations for information on personal-use filters and bottled water) (CIII). Current data are inadequate to support a recommendation that all HIV-infected persons boil or otherwise avoid drinking tap water in nonoutbreak settings. However, persons who wish to take independent action to reduce their risk for waterborne cryptosporidiosis may choose to take precautions similar to those recommended during outbreaks. Such decisions are best made in conjunction with a health-care provider. Persons who opt for a personal-use filter or bottled water should be aware of the complexities involved in selecting the appropriate products, the lack of enforceable standards for destruction or removal of oocysts, the cost of the products, and the difficulty of using these products consistently. Patients taking precautions to avoid acquiring cryptosporidiosis from drinking water should be advised that ice made from contaminated tap water also can be a source of infection (BII). Such persons should be aware that fountain beverages served in restaurants, bars, theaters, and other public places might also pose a risk, because these beverages, as well as the ice they might contain, are made from tap water. Nationally distributed brands of bottled or canned carbonated soft drinks are safe to drink. Commercially packaged noncarbonated soft drinks and fruit juices that do not require refrigeration until after they are opened (i.e., those that can be stored unrefrigerated on grocery shelves) also are safe. Nationally distributed brands of frozen fruit juice concentrate are safe if they are reconstituted by the user with water from a safe source. Fruit juices that must be kept refrigerated from the time they are processed to the time of consumption might be either fresh (unpasteurized) or heat-treated (pasteurized); only juices labeled as pasteurized should be considered free of risk from *Cryptosporidium*. Other pasteurized beverages and beers are also considered safe to drink (BII). No data are available concerning survival of *Cryptosporidium* oocysts in wine.

TRAVEL-RELATED EXPOSURES

1. Travel, particularly to developing countries, might result in significant risks for the exposure of HIV-infected persons to opportunistic pathogens, especially for patients who are severely immunosuppressed. Consultation with health-care providers and/or with experts in travel medicine will help patients plan itineraries (BIII).

2. During travel to developing countries, HIV-infected persons are at even higher risk for foodborne and waterborne infections than they are in the United States. Foods and beverages — in particular, raw fruits and vegetables, raw or undercooked seafood or meat, tap water, ice made with tap water, unpasteurized milk and dairy products, and items purchased from street vendors — might be contaminated (AII). Items that are generally safe include steaming hot foods, fruits that are peeled by the traveler, bottled (especially carbonated) beverages, hot coffee or tea, beer, wine, and water brought to a rolling boil for 1 minute (AII). Treating water with iodine or chlorine might not be as effective as boiling but can be used, perhaps in conjunction with filtration, when boiling is not practical (BIII).

3. Waterborne infections might result from swallowing water during recreational activities. To reduce the risk for cryptosporidiosis and giardiasis, patients should avoid swallowing water during swimming and should not swim in water that might be contaminated (e.g., with sewage or animal waste) (BII).

4. Antimicrobial prophylaxis for traveler's diarrhea is not recommended routinely for HIV-infected persons traveling to developing countries (DIII). Such preventive therapy can have adverse effects and can promote the emergence of drug-resistant organisms. Nonetheless, several studies (none involving an HIV-infected population) have shown that prophylaxis can reduce the risk for diarrhea among travelers (CDC. Health information for international travel, 1999–2000. Atlanta, Georgia: U.S. Department of Health and Human Services, 1999:202). Under selected circumstances (e.g., those in which the risk for infection is very high and the period of travel brief), the provider and patient may weigh the potential risks and benefits and decide that anti-biotic prophylaxis is warranted (CIII). For those persons to whom prophylaxis is offered, fluoroquinolones (e.g., ciprofloxacin [500 mg daily]) can be considered (CIII), although fluoroquinolones should not be given to children or pregnant women. Trimethoprim-sulfamethoxazole (TMP-SMZ) (one double-strength tablet daily) also has been shown to be effective, but resistance to this drug is now common in tropical areas. Persons already taking TMP-SMZ for prophylaxis against *Pneumocystis carinii* pneumonia (PCP) might gain some protection against traveler's diarrhea. For HIV-infected persons who are not already taking TMP-SMZ, health-care providers should be cautious in prescribing this agent for prophylaxis of diarrhea because of the high rates of adverse reactions and the possible need for the agent for other purposes (e.g., PCP prophylaxis) in the future.

5. All HIV-infected travelers to developing countries should carry a sufficient supply of an antimicrobial agent to be taken empirically should diarrhea develop (BIII). One appropriate regimen is 500 mg of ciprofloxacin twice a day for 3–7 days. Alternative antibiotics (e.g., TMP-SMZ) should be considered as empirical therapy for use by children and pregnant women (CIII). Travelers should consult a physician if their diarrhea is severe and does not respond to empirical therapy, if their stools contain blood, if fever is accompanied by shaking chills, or if dehydration develops. Antiperistaltic agents (e.g., diphenoxylate and loperamide) are used for the treatment of diarrhea; however, they should not be used by patients with high fever or with blood in the stool, and their use should be discontinued if symptoms persist beyond 48 hours (AII). Antiperistaltic agents are not recommended for children (DIII).

6. Travelers should be advised about other preventive measures appropriate for anticipated exposures (e.g., chemoprophylaxis for malaria, protection against arthropod vectors, treatment with immune globulin, and vaccination) (AII). They should avoid direct contact of the skin with soil or sand (e.g., by wearing shoes and protective clothing and using towels on beaches) in areas where fecal contamination of soil is likely (BIII).

7. In general, live-virus vaccines should be avoided (EII). One exception is measles vaccine, which is recommended for nonimmune persons. However, measles vaccine is not recommended for persons who are severely immunosuppressed (DIII); immune globulin should be considered for measles-susceptible, severely immunosuppressed persons who are anticipating travel to measles-endemic countries (BIII). Another exception is varicella vaccine, which may be administered to asymptomatic nonimmunosuppressed children (BII). Inactivated (killed) poliovirus vaccine should be used instead of oral (live) poliovirus vaccine, which is contraindicated for HIV-infected persons. Persons at risk for exposure to typhoid fever should be administered an inactivated parenteral typhoid vaccine instead of the live attenuated oral preparation. Yellow fever vaccine is a live-virus vaccine with uncertain safety and efficacy in HIV-infected persons. Travelers with asymptomatic HIV infection who cannot avoid potential exposure to yellow fever should be offered the choice of vaccination. If travel to a zone with yellow fever is necessary and vaccination is not administered, patients should be advised of the risk, instructed in methods for avoiding the bites of vector mosquitoes, and provided with a vaccination waiver letter.

8. In general, killed **and recombinant** vaccines (e.g., diphtheria-tetanus, rabies, hepatitis A, **hepatitis B**, Japanese encephalitis vaccines) should be used for HIV-infected persons just as they would be used for non-HIV-infected persons anticipating travel (BIII). Preparation for travel should include a review and updating of routine vaccinations, including diphtheria-tetanus for adults and all routine immunizations for children. The currently available cholera vaccine is not recommended for persons following a usual tourist itinerary, even if travel includes countries reporting cases of cholera (DII).

9. Travelers should be informed about other area-specific risks and instructed in ways to reduce those risks (BIII). Geographically focal infections that pose a high risk to HIV-infected persons include visceral leishmaniasis (a protozoan infection transmitted by the sandfly) and several fungal infections (e.g., *Penicillium marneffei* infection, coccidioidomycosis, and histoplasmosis). Many tropical and developing areas have high rates of tuberculosis.